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General Introduction and 








In this thesis the risk factors of venous thrombosis will be discussed in the general 
and particularly the elderly population. The goal of this thesis is to provide insights 
on risk factors of thrombosis in the elderly population, in order to advance our 
basic understanding of physiological age-related changes that increase the risk of 
venous thrombosis and which may ultimately lead to improved personalized 
interventions. In this chapter firstly background information will be provided on risk 
factors for venous thrombosis, focussing specifically on age as a risk factor. 
Secondly, the role of veins and venous valves in the development of venous 
thrombosis will be discussed and thirdly, global assays as a potential tool to 
identify patients at high risk for venous thrombosis will be considered. The study 
populations used in this thesis will discussed, and an outline of this thesis will be 
provided. 
Risk factors for venous thrombosis 
The process of thrombus formation depends on the balance of the procoagulant, 
anticoagulant, and fibrinolytic systems. In normal physiological circumstances, this 
thrombohemorrhagic balance is maintained in the body by interactions between 
the three systems, platelets, and the vessel wall.1 In individuals with venous 
thrombosis this balance is disrupted, leading to the formation of a blood clot in 
veins.2 In 1856 Virchow theorized three main causes of thrombosis: stasis of the 
blood, changes in the vessel wall, and changes in the composition of the blood.3 In 
the decades thereafter much effort has been put into identifying risk factors of 
venous thrombosis fitting in the three causes postulated by Virchow and this has 
resulted in an extensive list today, including environmental risk factors and genetic 
risk factors.4 
Age as a risk factor of venous thrombosis 
The global proportion of the elderly, aged 60 years and older increased from 9.2% 




Studies addressing the prevalence and contribution of risk factors of thrombosis 
have been performed almost entirely in young and middle-aged patient cohorts, 
whereas the incidence of thrombosis in the elderly is much higher. The overall 
incidence of a first symptomatic venous thrombosis in the general population is 1-2 
per 1000 person-years. In the age-group 25-30 years old, thrombosis occurs in 
approximately 1 per 10 000 person-years as compared with nearly 8 per 1000 
person-years in the 85 years and older population, as studied in an European 
cohort.6 In the Worcester Venous Thromboembolism Study, the incidence rates of 
venous thrombosis increased more than 10-fold in individuals aged ≥75 years, 
compared with patients aged <55 years.7 Several explanations have been 
hypothesized to explain the increasing incidence of thrombosis with age. Ageing 
may be associated with an increased prevalence of conventional established risk 
factors, development of new age-specific risk factors, accumulation of risk factors 
with age, and risk factors having synergistic effects in the aged.8 In this thesis we 
focus on conventional acquired (the airway diseases bronchitis, COPD, asthma, and 
venous insufficiency in chapters 2 and 4) and genetic risk factors of venous 
thrombosis (factor V Leiden rs6025 or prothrombin G20210A mutations rs1799963 
in chapter 3), but we also explore new age-specific risk factors (thickened venous 
valves in chapter 6), in anatomical areas where venous disease occurs most (as 
described in chapters 4 and 5).  
Pulmonary embolism and deep vein thrombosis in the elderly 
Venous thrombosis manifests itself as two entities, i.e., pulmonary embolism and 
deep vein thrombosis. From several studies it appears that risk factors of the two 
entities are to a large extent similar but also sometimes differ, questioning the 
consideration of deep vein thrombosis and pulmonary embolism as a single 
disease. This observation is particularly evident with the factor V Leiden mutation.9-
11 The prevalence of factor V Leiden has been consistently higher in patients with 
deep vein thrombosis than in patients with pulmonary embolism, known as the 
factor V Leiden paradox.12,13 In contrast, inflammatory lung diseases, such as 




embolism than deep vein thrombosis.14,15 We elaborate in this thesis on the 
differential effects of factor V Leiden and inflammatory lung diseases to pulmonary 
embolism and deep vein thrombosis.  
Veins and valves in the elderly 
In 1851, Virchow observed a left-sided predominance of deep vein thrombosis of 
the legs and hypothesized that compression of the left common iliac vein by the 
right common iliac artery could be the underlying cause.16 Over a hundred years 
later, May and Turner stated that venous webs or spurs had formed at the point of 
the compression,17 causing the left-sided predominance. Pregnancies and hormone 
use have been related to left-sided thrombus distribution in women.18,19 In the 
elderly, a population in which hormones and pregnancies do not play a role, the 
question arises whether the thrombus left-right distribution changes. In this thesis 
we aim to investigate this.  
Venous valves in the veins of the lower extremities play a role in maintaining the 
blood flow back to the heart. Venous valves are usually bicuspid,20,21 provide 
unidirectional flow,22 and close as the valve leaflets move towards the centre of the 
vein.23 Valves are located in a valve sinus, a local widening of the venous wall. The 
area between the valve leaflet and vessel wall, i.e., the valve pocket, is viewed as 
the predominant location of thrombus inititation (Figure 1) 24. In the deepest part 
of the valve pockets, blood circulates with very low velocities creating a low shear 
field, allowing red cells to aggregate.24 Stasis of blood in the pocket leads to 
hypoxia, causing endothelial activation and activation of the coagulation system. 
Age-related changes of venous valves have been described in several ex-vivo 
studies, showing thickening of valves with age in renal and in femoral veins.25,26 
The thickening of the valves was shown to be the result of atrophy of muscle 
fibers, hypertrophy of elastic fibers, and an increased number of collagen fiber 
bundles.26 One in vivo study showed thickening of venous valves with age in 
healthy individuals, measured by ultrasound examinations.27 Ageing of venous 




venous thrombosis. In chapter 6 we conduct a case-control study to examine the 
risk of venous thrombosis associated with thickened venous valves in the popliteal 
fossa. Furthermore, we investigate whether venous reflux, measured by the valve 
closure time, relates to the risk of thrombosis, as venous reflux contributes to 
stasis and might therefore add to the risk of thrombosis. For this reason, in chapter 
4 we focus on clinical signs of venous insufficiency, such as history of varicose 
veins, leg ulcer, leg oedema and the risk of thrombosis.  
 
 
Figure 1 Schematic drawing of the vortical flow in the deep venous system. The flow 
arrows define the genesis of the two counter rotating vortices within the valve sinus. The 
small vortex at the base of the valve sinus is isolated from the systemic circulation and is 
congruent with the region of most marked hypoxia, which is the usual site of valvular sinus 





To minimize the global burden of venous thrombosis on health, timely diagnosis, 
risk stratification, and monitoring of treatment with haemostatic agents become 
crucial. From this background the need for global assays emerged and they 
advanced our understanding of blood coagulation dynamics in individuals.28 The 
utility of global assays is still debated, but the thrombogram and 
thromboelastographic methodologies are two global assays that have proceeded 
into clinical evaluation.28 Since it has been difficult to establish the risk of recurrent 
venous thrombosis using clinical factors, attempts have been made to identify 
global laboratory markers which are associated with an increased risk of a 
recurrent thrombosis.29 In chapter 7 we investigate whether clot lysis time, which 
measures the plasma fibrinolytic potential,30 is a candidate to identify patients with 
an increased risk of a first and recurrent venous thrombosis.  
Clinical studies used in this thesis 
The analyses described in this thesis are performed in three different clinical 
studies: the AT-AGE (Age and Thrombosis, Acquired and Genetic risk factors in 
the Elderly) study, the Batavia (Biology of Ageing and Thrombosis: Appraisal of 
Valve thickness and function, an In vivo Assessment) study, and the THE-VTE 
(Thrombophilia, Hypercoagulability and Environmental risks in Venous 
ThromboEmbolism) study.  
The AT-AGE study 
The AT-AGE study is a two-center, population-based case-control study in Leiden 
and Vermont designed to study risk factors for venous thrombosis specifically in 
the elderly. Cases aged 70 years and older were included from anticoagulant clinics 
in Leiden and Haarlem in the Netherlands and in University of Vermont Medical 
Center in Burlington, Vermont. Controls were invited from several primary care 
practices in the same geographical area. As the elderly are often excluded from 




center, visual and cognitive impairments or comorbidities, home visits were 
conducted to reach high participation rate. During the home visits, interviews were 
performed and questionnaire data and blood samples were collected. 401 cases 
with a first-time thrombosis and 431 control subjects that never had experienced 
thrombosis were included and visited. Inclusion started in 2008 and was completed 
in 2011. Chapters 2 to 5 are based on data from the AT-AGE study.  
The Batavia study 
In the Batavia study we examined the relation between thickened venous valves in 
the popliteal vein and the risk of venous thrombosis. Age-related changes of the 
venous valves, have been described in several studies. Histology studies have 
shown an increased collagen deposition and thickening of the lamina elastic with 
age.26 Furthermore, clinical studies related increasing age to thickening of venous 
valves as measured by ultrasound examination.27 All previous studies were 
performed in healthy individuals, whereas in the Batavia study we examined the 
association between thickened venous valves and venous thrombotic disease. 
Cases with a deep vein thrombosis and controls from the AT-AGE study were 
approached to participate in the Batavia study. All participants were aged ≥70 
years. Participants were invited to the LUMC for an ultrasound examination to 
visualize and measure the thickness of the valve in the popliteal vein, if present. 
The Batavia study is described in detail in chapter 6.  
THE-VTE study 
The aim of the THE-VTE study is to determine whether a global testing strategy 
enables the indentification ofan increased clotting tendency (hypercoagulability) 
and as such the identification of individuals at increased risk of  a first and 
recurrent venous thrombosis. Cases in the Netherlands were identified at the 
anticoagulation clinic in Leiden and in the United Kingdom cases were identified at 
the Addenbrooke’s Hospital in Cambridge. Partners were approached to participate 




clot lysis time and the risk of venous thrombosis, both first and recurrent, studied 
in the THE-VTE study, is discussed in chapter 7.  
Outline of this thesis 
The aim of this thesis is to provide insight into risk factors for venous thrombosis in 
the elderly. We focussed on airway diseases in the elderly, and the risk of deep 
vein thrombosis and pulmonary embolism, both combined and separately in 
chapter 2. We hypothesized that since risk factors for deep vein thrombosis and 
pulmonary embolism differ in the middle-aged population, the effect of airway 
diseases will also be greater on pulmonary embolism than on deep vein thrombosis 
in the elderly. Next, chapter 3 focusses on the question whether the most 
common genetic risk factors for venous thrombosis, i.e., the factor V Leiden and 
prothrombin G20210A variants, and non-O blood group, as well as a positive family 
history of VT, are risk factors for a first venous thrombosis at an older age. It is 
well known that these factors are associated with an increased risk of thrombosis 
in the middle-aged population, but the effect at older age has not been thoroughly 
studied. Clinical manifestations of venous insufficiency, such as a history of 
varicose veins, leg ulcer and leg oedema, are discussed in chapter 4. The 
anatomical thrombi distribution in the elderly is described in chapter 5. Chapter 
6 presents the data of the Batavia study, in which we investigate the role of 
venous valves in the popliteal vein on the risk of venous thrombosis.  
Additional to an increased coagulation tendency, a decreased fibrinolytic capacity 
might also increase the risk of thrombosis in the general population. As an 
inspection of usage of global assays measuring decreased fibrinolysis in the 
middle-aged population, chapter 7 was dedicated to the global assay clot lysis 
time. Analyses were performed in THE VTE study, which consists of participants 
aged 18-75 years. 
Finally, chapter 8 summarizes the findings of this thesis, places the main findings 
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Airway diseases in elderly people are 
associated with pulmonary embolism 
but not deep vein thrombosis 
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Pulmonary embolism (PE) has long been thought to exclusively originate from a 
deep vein thrombosis (DVT), but recent studies suggest this may not always hold 
true in middle-aged populations with inflammatory airway diseases. We aimed to 
study the association between different airway diseases (chronic obstructive 
pulmonary disease – COPD, asthma and bronchitis) and venous thrombosis (VT) in 
a case-control study of elderly (>70 years) participants. 401 cases with a first-time 
VT and 431 controls without VT were included in the two-center AT-AGE study. 
Information on airway diseases was obtained from questionnaires during home 
visits. Bronchitis was associated with a 1.5-fold (95%CI: 0.9-2.4) increased VT risk, 
with similar risk estimates for DVT and PE. Individuals with COPD had a 1.8-fold 
increased risk of VT compared with individuals without COPD (95%CI: 1.1-3.0). 
The increased risk was limited to an increased risk of PE (OR 2.5, 95%CI: 1.4-4.4) 
while there was no association with DVT (OR 1.0, 95%CI: 0.4-2.1). Individuals 
with asthma only had a mildly increased risk of VT (OR 1.4, 95%CI: 0.7-2.8); 
again the risk was limited to PE: OR 1.9, 95%CI: 0.8-4.1; DVT: OR 0.8, 95%CI: 
0.3-2.4. When analysing the risk of VT for all airway diseases combined, we found 
a 1.7-fold increased risk (95%CI: 1.2-2.4) for all VT; 2.2-fold (95%CI:1.5-3.3) for 
PE and 1.2-fold (95%CI: 0.7-1.9) for DVT. We conclude that inflammatory airway 
diseases in the elderly, i.e. bronchitis, COPD, asthma are associated with an 





Venous thrombosis (VT) mainly manifests as pulmonary embolism (PE) and deep 
vein thrombosis (DVT). Many factors affect the risk of both DVT and PE, but some 
differ; those associated with increased APC-resistance, e.g. factor V Leiden and 
obesity, are more often seen in patients with DVT, whereas pulmonary 
inflammatory diseases, such as chronic obstructive pulmonary disease, pneumonia, 
and sickle cell disease are predominantly associated with increased risk of PE.[1,2] 
PE has long been thought to exclusively originate from a DVT, but recent studies 
suggest that this may not always hold true.[1] Other sources such as cardiac 
thrombi in patients with atrial fibrillation have been postulated. It has also been 
suggested that PE develops de novo in the lung.[3,4] Inflammatory processes in 
the respiratory tract can stimulate the coagulation system, as seen in a recent 
study on pneumonia and VT.[5] Pneumonia increases the risk of VT substantially, 
while it is yet unknown whether this is also the case for airway diseases such as 
bronchitis, chronic obstructive pulmonary disease (COPD) or asthma in an elderly 
population.  
PE is an important cause of death in elderly people[6], and has a high incidence in 
this age group.[7,8] However, most studies on risk factors have focussed on young 
or middle-aged individuals. Considering the rising incidence of VT in the elderly 
and the high death rate from PE in this age group and in the general 
population[9], there is a need for studies focussing on risk factors specifically for 
DVT or PE in an older population.  
The aim of this study was to evaluate the associations of three inflammatory 
airway diseases: bronchitis, COPD, asthma and risk of VT in a population-based 
case-control study of people aged 70 years and older. We also assessed the impact 




Materials and methods  
Study design and population 
The AT-AGE study (Age and Thrombosis: Acquired and Genetic risk factors in the 
Elderly) is a bicenter population-based case-control study performed in Leiden, The 
Netherlands and Burlington, Vermont, the United States. A detailed description of 
the study, including participant characteristics by center, was published 
previously.[10] In short, from June 2008 to August 2011 in Leiden and December 
2008 to July 2011 in Vermont, all consecutive patients 70 years and older with DVT 
or PE were identified in anticoagulation clinics in Leiden and Haarlem (The 
Netherlands) and at the Vascular Laboratory and the Radiology department of the 
University of Vermont Medical Center (Burlington, Vermont, United States). We 
defined venous thrombosis as deep venous thrombosis of the leg (DVT) or 
pulmonary embolism (PE). Control subjects were identified in Leiden and 
Burlington in the same geographic area as the patients. Control subjects were 
randomly selected from five primary care practices in Leiden and four in 
Burlington. Individuals were excluded from participation if they reported that they 
had an active malignancy, defined as diagnosis of cancer within six months before 
the thrombotic event (or date of telephone call for the control subjects) or received 
chemotherapy or radiation therapy for cancer in the last six months. Furthermore, 
those with severe cognitive or psychiatric disorders or who reported a previous 
DVT or PE were also excluded. Approval for this study was obtained from the 
Medical Ethics Committee of the Leiden University Medical Center and by the 
Committee of Human Research of the University of Vermont. All participants 
provided written informed consent.  
Risk factor assessment  
During home visits a detailed structured interview on risk factors for venous 
thrombosis was performed by trained personnel. The questions concerned self-




current medications, confirmed by examining pill bottles. There were no missing 
data on bronchitis, COPD or asthma. Individuals were classified as having 
bronchitis, COPD or asthma if they answered yes to questions on the presence of 
these conditions or if they were taking any of the following medications used to 
treat these disorders: shortacting anticholinergics, shortacting beta2 agonists, 
longacting beta2 agonists, inhaled corticosteroids, or combinations. Smokers were 
divided into current, former, and never smokers. The index data was the date of 
the thrombotic event for VT patients and for the control subjects this was the date 
of filling in the questionnaire. Body mass index (BMI) was calculated by dividing 
body weight (kg) by squared height (m2). 
Blood samples were drawn into vacuum tubes containing 0.1-volume 0.106-mol/L 
trisodium citrate. The blood sample was separated into plasma and cells through 
centrifugation. DNA analysis for the factor V Leiden (G1691A) mutation was 
performed using a combined polymerase chain reaction method with use of the 
TaqMan assay. Heterozygotes and homozygotes were combined for analysis. 
Statistical analysis 
Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess 
the risk of VT with presence of bronchitis, COPD or asthma considered separately 
and in combination with presence of factor V Leiden. Risk estimates were adjusted 
for potential confounders, i.e., for age (continuous), sex, smoking status (current, 
former, never), BMI and study center (Leiden and Haarlem vs Burlington) by using 
multivariable logistic regression analysis. Separate analyses were performed for 
type of thrombosis, i.e., DVT and PE (±DVT). We carried out a sensitivity analysis 
classifying participants who did not report an airway disease as having an airway 
disease based on use of 1 or more medications used for airway diseases. Since 
systemic steroids are used as treatment for bronchitis, COPD and asthma and are 
associated with an increased risk of venous thrombosis, as reviewed by Van Zaane 
et al[11], we calculated ORs stratified on systemic steroid use. IBM SPSS Statistics 





The study included 401 patients of whom 166 had a DVT only and 235 had a PE 
with or without DVT, and 431 control subjects (Table 1). Patients were slightly 
older than control subjects, with a median age among patients of 78 years (range 
70-101), and among control subjects 76 years (range 70-96). Patients were more 
often women than controls and had a similar BMI. In total, 106 (26%) patients and 
78 (18%) control subjects reported a diagnosis of bronchitis, COPD or asthma 
before the index date. Of the patients, 48 (12%) reported bronchitis, 43 (11%) 
COPD and 19 (5%) asthma. In control subjects, these conditions were less 
common: 37 (9%) with bronchitis, 29 (7%) with COPD and 19 (4%) with asthma. 
Patients with PE ± DVT reported a history of airway diseases more often (N=71, 
18%) than patients with DVT (N=35, 9%). Factor V Leiden data was available in 
394 patients and 426 control subjects. Sensitivity analyses showed no difference 
between classifying individuals based only on their reported airway disease and 
classifying individuals based on their reported airway disease and usage of the 
indicated medication.    
Airway diseases and the risk of VT 
Individuals with bronchitis had a 1.5-fold increased risk of venous thrombosis 
compared with individuals without bronchitis (Table 2, OR 1.5, 95% CI 0.9-2.4). 
The increased risk was slightly higher for PE than DVT (ORs 1.6, 95% CI: 0.9-2.8 
for PE and 1.4, 95% CI: 0.8-2.6 for DVT). Individuals with COPD had a 1.8-fold 
increased risk of venous thrombosis compared with individuals without COPD (OR 
1.8, 95%CI: 1.1-3.0). The increased risk was limited to an increased risk of PE (OR 
2.5, 95% CI: 1.4-4.4) while there was no association with DVT (OR 1.0, 95% CI 
0.4-2.1). For asthma there was no overall increased risk of VT (OR 1.4, 95% CI 
0.7-2.8), and a 1.9-fold increased risk of PE (95% CI: 0.8-4.1). When analysing the 
risk of VT for all airway diseases combined, there was a 1.7-fold increase in risk 
(OR 1.7, 95% CI 1.2-2.4), with a higher risk for PE (OR 2.2, 95% CI 1.5-3.3) than 




corticosteroids, the risks were similar, individuals with any of the three airway 
diseases had an increased risk of PE (OR 1.8, 95% CI: 1.1-2.8) but not, or only 
weakly of DVT (OR 1.3, 95% CI: 0.8-2.2).  
 
Table 1 Baseline characteristics patients and controls  
  Patients Controls 
N 401 431 
Men, n (%) 166 (41) 209 (49) 
Age, years (range) 79 (70-101) 78 (70-96) 
Type VT, N (%) 
Deep vein thrombosis 







Systemic corticosteroid use, N (%) 11 (2.7) 11 (2.6) 
Factor V Leiden, N (%) 34 (8.5) 18 (4.2) 















Association of factor V Leiden and airway diseases on the risk of VT 
Factor V Leiden was present in 19 of 162 patients with DVT (11.7%) and 15 of 232 
patients with PE with or without DVT (6.5%), while it was present in 18 of 426 
control subjects (4.2%). Two patients had the homozygous mutation. The risk of 
DVT with factor V Leiden was 3-fold increased (OR 3.0, 95% CI: 1.5-6.0), while 
the risk of PE was only mildly increased (OR 1.5, 95% CI: 0.7-3.1).  
We analysed the combined effect of having any of the three airway diseases (i.e., 
bronchitis, COPD or asthma) and factor V Leiden on the risk of VT, with results 
shown in table 3. With individuals without any airway disease and not carrying the 
factor V Leiden mutation as a reference category, individuals with any of the 
airway diseases had a 1.6-fold increased risk of VT. In absence of airway diseases, 
factor V Leiden was associated with 1.7-fold increased risk of VT. In patients with 
both an airway disease and factor V Leiden, the OR for VT was 13.2. Patterns of 
association were similar in those with DVT and PE, with the highest among those 




















































































































































































































































































































































































































































































































































































































































































































































































































































In this population-based case-control study among individuals aged 70 years and 
older the presence of either bronchitis, COPD or asthma was associated with the 
risk of PE (ORs ranging 1.6-2.5), and not or only weakly, with the risk of DVT (ORs 
ranging 1.0-1.4). The risk of VT associated with airway diseases was most 
pronounced in carriers of the factor V Leiden mutation (OR 13.2), with the 
combined association for airway diseases and the factor V Leiden being high for 
both PE (OR 14.8) and DVT (OR 9.8).  
We are not aware of other studies that investigated the relationship between these 
airway diseases combined with the presence of factor V Leiden and risk of VT in an 
older population. Several studies have reported an association between COPD and 
PE.[12,13] The first study included only participants below age 70 years, the 
second study limited the analysis to a primary care setting and participants under 
age 79, and the third study also included patients who had a prior VT history, so 
these were not incident cases. In many studies an association between 
inflammation, such as seen in asthma, and enhanced coagulation was 
suggested.[14,15] A prospective study found a 3.5-fold increased risk of PE in 
patients with mild-to-moderate asthma [16], and IL-8 levels were associated with 
a 1.9-fold increased risk of VT in a case-control study.[17] While there was little 
association of asthma and PE in our study, power was limited by the relatively 
small numbers of participants with asthma. Our results show that patients with 
COPD, asthma or bronchitis  are indeed at increased risk of PE.  
The factor V Leiden paradox is the observation that this genetic variant mainly 
affects the risk of PE.[18,19] In our current study the ‘factor V Leiden paradox’ 
was also present in older people: individuals with FVL had a pronounced risk of 
DVT but not of PE (OR=3.0 vs OR=1.5), and this difference was still present when 
we excluded patients with airway diseases. While factor V Leiden affects the risk of 
PE only very mildly, we observed that in combination with presence of airway 




individuals in this subgroup, definitive conclusions  require confirmation by other 
studies. 
Several causal explanations for our results may be hypothesized. Inflammatory 
airway diseases may predispose to a local prothrombotic state and therefore give 
rise to a local development of pulmonary thrombi which embolize within the 
pulmonary vasculature. Asthma is associated with a procoagulant state in the 
bronchoalveolar space in the lungs, via an increase in tissue factor activity.[14] 
The pulmonary arteries of COPD patients are characterised by endothelial cell 
dysfunction which in turn also leads to a procoagulant state.[20] Furthermore, 
COPD patients have increased FVIII, FIX, prothrombin and thrombin levels, leading 
to a prothrombotic tendency.[21] Similar mechanisms might hold for chronic 
bronchitis. The effects of C-reactive protein, a biomarker of inflammation, on 
haemostasis has been reviewed by Fay, demonstrating a link between 
inflammation and thrombosis.[22] These consistent results of associations between 
pulmonary inflammatory diseases and pulmonary thrombi make a local 
development of these thrombi plausible. The role of usage of corticosteroids should 
also be considered, as these are often prescribed for patients with airway diseases 
and their usage has been linked to a hypercoagulable state.[11,23] However, 
excluding the few participants using these medications did not alter our results.  
Our study has several limitations. Firstly, data on airway diseases were self-
reported. No functional tests were performed to diagnose the airway diseases and 
self-reports were not confirmed by medical record review. Participants could have 
misclassified their specific airway condition (bronchitis, COPD or asthma). 
However, as all investigated airway conditions are chronic, this misclassification is 
likely to be random and similar in patients and control subjects, which would at 
most result in an underestimation of the risks.[24] Moreover, COPD is usually 
underdiagnosed[25], again leading to underestimation of the risk. Secondly, we did 
not have information on the severity of COPD, asthma or bronchitis, which was 




risk of PE.[16] Thirdly, the diagnosis of PE is difficult to establish in COPD patients 
with exacerbations. However, all PE diagnoses were confirmed by imaging and 
symptomatic PE is unlikely to remain undiagnosed. Fatal PE may have been missed 
since the presentation of PE can be as sudden death, and this would lead to an 
underestimation of the risks. Fourthly, due to the relatively low numbers of 
patients with airway diseases, particularly when analysed in subgroups of the three 
airway diseases and FVL, the confidence intervals of the odds ratios are wide and 
not discriminatory. Lastly, we could not distinguish between patients who had an 
isolated PE and those who had both PE and DVT, as un ultrasound examination of 
the lower extremities is not standard care when patients present with PE 
complaints. This would dilute our results. The strengths of our study include the 
large patient sample of individuals aged 70 years and older, the detailed 
assessment of risk factors for thrombosis, and the home visits for collection of 
measured risk factors.  
The findings of our study might have important clinical implications. PE is a 
potentially life-threatening complication of VT which is also more prevalent in the 
older population than the middle-aged population.[26] The interaction of airway 
diseases and factor V Leiden that we observed, if it can be confirmed, suggests a 
high attributable risk for this combination of risk factors in this age group. For 
example, an individual with airway disease and factor V Leiden who is over age 80 
may have as high as a 10% annual risk of PE. Physicians should therefore be more 
aware that patients with an airway disease are at risk of PE. 
In conclusion, older individuals with airway disease had a higher risk of VT than 
individuals without an airway disease and the risk was most pronounced for PE 
than for DVT. The risk was highest when the factor V Leiden mutation was 




 1 van LK, Flinterman LE, van H, V, Rosendaal FR, Cannegieter SC. Broadening the factor V Leiden 
paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood 
2012; 120: 933-46. 
 2 Folsom AR, Tang W, Roetker NS, Kshirsagar AV, Derebail VK, Lutsey PL, Naik R, Pankow JS, 
Grove ML, Basu S, Key NS, Cushman M. Prospective study of sickle cell trait and venous 
thromboembolism incidence. J Thromb Haemost 2015; 13: 2-9. 
 3 Velmahos GC, Spaniolas K, Tabbara M, Abujudeh HH, de MM, Gervasini A, Alam HB. Pulmonary 
embolism and deep venous thrombosis in trauma: are they related? Arch Surg 2009; 144: 928-
32. 
 4 Schwartz T, Hingorani A, Ascher E, Marks N, Shiferson A, Jung D, Jimenez R, Jacob T. 
Pulmonary embolism without deep venous thrombosis. Ann Vasc Surg 2012; 26: 973-6. 
 5 Ribeiro DD, Lijfering WM, Van H, V, Rosendaal FR, Cannegieter SC. Pneumonia and risk of 
venous thrombosis: results from the MEGA study. J Thromb Haemost 2012; 10: 1179-82. 
 6 Merli GJ. Pathophysiology of venous thrombosis, thrombophilia, and the diagnosis of deep vein 
thrombosis-pulmonary embolism in the elderly. Clin Geriatr Med 2006; 22: 75-ix. 
 7 Berman AR. Pulmonary embolism in the elderly. Clin Geriatr Med 2001; 17: 107-30. 
 8 Kniffin WD, Jr., Baron JA, Barrett J, Birkmeyer JD, Anderson FA, Jr. The epidemiology of 
diagnosed pulmonary embolism and deep venous thrombosis in the elderly. Arch Intern Med 
1994; 154: 861-6. 
 9 Sogaard KK, Schmidt M, Pedersen L, Horvath-Puho E, Sorensen HT. 30-year mortality after 
venous thromboembolism: a population-based cohort study. Circulation 2014; 130: 829-36. 
 10 Engbers MJ, Blom JW, Cushman M, Rosendaal FR, van H, V. The contribution of immobility risk 
factors to the incidence of venous thrombosis in an older population. J Thromb Haemost 2014; 
12: 290-6. 
 11 van ZB, Nur E, Squizzato A, Gerdes VE, Buller HR, Dekkers OM, Brandjes DP. Systematic review 
on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J 
Thromb Haemost 2010; 8: 2483-93. 
 12 Schneider C, Bothner U, Jick SS, Meier CR. Chronic obstructive pulmonary disease and the risk 
of cardiovascular diseases. Eur J Epidemiol 2010; 25: 253-60. 
 13 Bertoletti L, Quenet S, Mismetti P, Hernandez L, Martin-Villasclaras JJ, Tolosa C, Valdes M, 
Barron M, Todoli JA, Monreal M. Clinical presentation and outcome of venous thromboembolism 
in COPD. Eur Respir J 2012; 39: 862-8. 





 15 Levi M, van der Poll T, Buller HR. Bidirectional relation between inflammation and coagulation. 
Circulation 2004; 109: 2698-704. 
 16 Majoor CJ, Kamphuisen PW, Zwinderman AH, Ten BA, Amelink M, Rijssenbeek-Nouwens L, Sterk 
PJ, Buller HR, Bel EH. Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur 
Respir J 2013; 42: 655-61. 
 17 van Aken BE, Reitsma PH, Rosendaal FR. Interleukin 8 and venous thrombosis: evidence for a 
role of inflammation in thrombosis. Br J Haematol 2002; 116: 173-7. 
 18 Desmarais S, de MP, Reber G, Minazio P, Perrier A, Bounameaux H. Resistance to activated 
protein C in an unselected population of patients with pulmonary embolism. Lancet 1996; 347: 
1374-5. 
 19 Bounameaux H. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary 
embolism. Lancet 2000; 356: 182-3. 
 20 Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. 
Eur Respir J Suppl 2003; 46: 28s-32s. 
 21 Undas A, Jankowski M, Kaczmarek P, Sladek K, Brummel-Ziedins K. Thrombin generation in 
chronic obstructive pulmonary disease: dependence on plasma factor composition. Thromb Res 
2011; 128: e24-e28. 
 22 Fay WP. Linking inflammation and thrombosis: Role of C-reactive protein. World J Cardiol 2010; 
2: 365-9. 
 23 COSGRIFF SW, DIEFENBACH AF, VOGT W, Jr. Hypercoagulability of the blood associated with 
ACTH and cortisone therapy. Am J Med 1950; 9: 752-6. 
 24 Flegal KM, Brownie C, Haas JD. The effects of exposure misclassification on estimates of relative 
risk. Am J Epidemiol 1986; 123: 736-51. 
 25 Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, Heels-Ansdell DM, Erak M, 
Bragaglia PJ, Tamari IE, Hodder R, Stanbrook MB. Prevalence and underdiagnosis of chronic 
obstructive pulmonary disease among patients at risk in primary care. CMAJ 2010; 182: 673-8. 
 26 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ, III. Trends in the 
incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. 












Genetic risk factors for venous 




Marissa J. Engbers 
Mary Cushman 
Frits R. Rosendaal 
Astrid van Hylckama Vlieg 
 






As the incidence of VT increases steeply with age and the number of elderly is on 
the rise, studies of VT in this age group are important. We aimed to study the 
associations of common genetic risk factors, i.e., the factor V Leiden and 
prothrombin G20210A mutations, non-O blood group, and family history of VT with 
risk of a first VT in older age (>70 years). 401 consecutive cases with a first-time 
thrombosis and 431 controls (all ≥70 years) were included in the AT-AGE case-
control study. Information on risk factors for VT, including family history of VT in 
first degree relatives, was obtained by interview. Unprovoked VT was defined as 
thrombosis not related to surgery, fracture, plaster cast or immobility within three 
months prior to VT. The risk of VT was 2.2-fold increased in factor V Leiden 
carriers (95% CI 1.2-3.9), 1.4-fold increased in prothrombin mutation carriers 
(95% CI 0.5-3.9), and 1.3-fold increased in those with non-O blood group (95% CI 
1.0-1.8). Positive family history of VT  was associated with a 2.1-fold increased risk 
of VT (95% CI 1.5-3.1). The highest risk of VT was found in individuals who had 
both a positive family history and were carriers of one of  the two prothrombotic 
mutations. Genetic factors clearly related to VT in younger populations were also 
risk factors in older age, and a positive family history was also important in this 





Venous thrombosis (VT) is a multicausal disease, associated with both 
environmental and genetic risk factors.[1] Factor V Leiden (rs6025) and the 
prothrombin G20210A mutation (rs1799963) are the most common prothrombotic 
variants (prevalence of 3-5%) in young and middle aged population and are 
associated with a 3-7-fold increase in the risk of VT compared with non-carriers.[2-
4] Another genetically determined risk factor, i.e., the non-O blood group, is an 
important determinant of venous and arterial disease.[5-7] In the young and 
middle-aged population, blood group non-O is associated with a doubling in risk of 
VT.[8] Family history is a feasible and comprehensive genetic risk assessment 
method for VT, potentially useful to detect thrombophilia in patients, as reviewed 
by Zöller et al.[9] Aggregation of VT cases in a family may reflect the presence of 
known and unknown genetic risk factors. However, conflicting results are published 
regarding a positive family history as a predictor for the presence of inherited 
thrombophilia.[10-13]  
Limited information is available regarding genetic risk factors for VT in the elderly. 
Elderly persons are often excluded from clinical studies into aetiology and 
management because of co-morbidities, short life expectancies, and logistical 
difficulties.[14, 15] Furthermore, it is unknown whether a positive family history of 
VT is predictive of a venous thrombotic event at an older age. As the incidence of 
VT increases strongly with age and the number of elderly is on the rise[16], 
studies of VT in the elderly becomes more relevant: VT is rare in young individuals 
(<1 per 10 000 per year under the age of 18) but increases to nearly 1% per year 
at very old age.[16] 
This study aimed to assess whether common genetic risk factors, i.e., the factor V 
Leiden and prothrombin G20210A mutations, non-O blood group, as well as a 
positive family history of VT are risk factors for a first VT at an older age (>70 




history of VT for factor V Leiden, prothrombin G20210A and non-O blood group in 
this age group.  
Methods 
Study population and data collection 
The Age and Thrombosis, Acquired and Genetic risk factors in the Elderly (AT-AGE) 
study is a two-center, population-based case-control study designed to study risk 
factors for VT in the elderly. The study design was described in detail 
previously.[17] From June 2008 to August 2011 in Leiden, the Netherlands and 
December 2008 to July 2011 in Burlington, Vermont, US, all consecutive patients 
70 years and older with a first DVT or PE were identified. Cases were identified 
from the anticoagulation clinics in Haarlem and Leiden and from the Vascular 
Laboratory and the Radiology department of the University of Vermont Medical 
Center. Controls were randomly selected from five primary care practices in Leiden 
and four in Vermont. Subjects with an active malignancy or severe psychiatric or 
cognitive disorder were excluded. For all participants, a home visit took place, 
during which an extensive structured interview was completed by trained 
personnel and a blood sample or buccal swab was collected. The index date was 
defined as the date of diagnosis of the thrombosis for the cases and the date of 
the home visit for the controls. All participants provided written informed consent. 
The study was approved by the Medical Ethical Committee of the Leiden University 
Medical Center and by the Committee of Human Research of the University of 
Vermont.  
Risk factor assessment 
Self-reported information on the presence of first-degree relatives (parent, sibling, 
or offspring) who experienced VT was obtained via the interview. Family history of 
VT was considered positive if at least one first degree relative experienced VT. 
Participants who indicated that they did not know whether a first degree relative 




Provoked VT was defined as thrombosis after hospitalisation, fracture, plaster cast, 
splint or transient immobility at home ≥4 consecutive days in the three months 
before the index date.  
During the home visits, blood samples were drawn into vacuum tubes containing 
0.1-volume 0.106-mol/L trisodium citrate or when no blood sample could be drawn 
a buccal swab was collected (N=28). The blood sample was separated into plasma 
and cells through centrifugation. DNA analysis for the factor V Leiden mutation 
(rs6025) and the prothrombin G20210A mutation (rs1799963) was performed 
using a combined polymerase chain reaction method with the TaqMan assay. The 
20146G/- (rs8176719), 21463C/G (rs7853989), 21867A/G (rs8176749), and 
21996C/- (rs8176750) blood group polymorphisms were determined by a 
5’nuclease assay (Taqman; Applied Biosystems, Foster City, CA, USA) using a PCR 
reaction mix (Taqman Genotyping Master Mix, Applied Biosystems) and an allele-
specific fluorescent probe equipped with a minor groove binding moiety (Applied 
Biosystems).  
Statistical analysis 
To estimate relative risks, we calculated odds ratios (ORs) with 95% confidence 
intervals (95% CI) using logistic regression. We determined associations of factor 
V Leiden, the prothrombin G20210A mutation,  ABO blood group, and a positive 
family history with VT risk. All ORs were adjusted for age (continuous), sex 
(categorical), and study center (Leiden and Haarlem versus Vermont, categorical) 
using multivariable logistic regression. Additional to the individual associations, the 
combined associations of the risk factors were studied. Analyses were also 
stratified for provoked and unprovoked VT, and type of VT (DVT only or PE with or 
without DVT). Sensitivity analysis excluded individuals who did not know their 
family history status for VT. The risk of VT associated with a positive family history 
of VT was also studied in more detail by calculating ORs for having any affected 
first-degree relative, having a first-degree relative affected before age 50, and for 




value of family history to identify factor V Leiden, prothrombin G20210A mutation 
or ABO blood group. The population attributable risk (PAR) is an estimate of the 
burden of a disease.[18] The PAR of factor V Leiden, prothrombin G20210A 
mutation, non-O blood group and a positive family history of VT was calculated 
using the formula: p x (OR – 1)/(OR), in which p is the proportion of cases 
exposed to the risk factor. IBM SPSS Statistics 20.0 for Windows (SPSS Inc, 
Chicago, Ill) was used for data analysis.  
Results 
In this study, 401 patients and 431 controls were included (Table 1); 166 patients 
(41%) were diagnosed with an isolated DVT and 235 (59%) with PE with or 
without DVT. DNA analysis for factor V Leiden was available for 394 (98%) 
patients and 426 (99%) controls, for prothrombin G20210A mutation for 394 
(98%) patients and 427 (99%) controls and for ABO blood group for 376 (94%) 
patients and 416 (97%) controls. Of all participants, 25 (6%) patients and 13 (3%) 
controls did not know whether one of their first degree relatives had VT. In the 







Table 1 Baseline characteristics patients and controls 
  Controls Patients 
N 431 401 
Men, N (%) 209 (48.5) 166 (41.4) 
Age, mean (range) 77.5 (70-96) 78.7 (70-101) 
Type VT, N (%) 
   Deep vein thrombosis (DVT) 
   Pulmonary embolism (PE) (±DVT) 









Factor V Leiden, N (%) 18 (4.2) 34 (8.6) 
Prothrombin G20210A mutation, N (%) 7 (1.6) 9 (2.3) 
Non-O blood group, N (%) 232 (55.8) 231 (61.4) 
Positive family history for VT, N (%) 54 (12.5) 97 (24.2) 
 
*defined as thrombosis after hospitalisation, fracture, plaster cast, splint, or transient 
immobility at home in the three months before the index date.  




Prothrombotic variants, ABO blood group and risk of VT 
Out of 394 patients, 34 (8.6%) carried factor V Leiden (32 heterozygotes and 2 
homozygotes). Of the controls, 18 (4.2%) were heterozygous for factor V Leiden 
and none were homozygous. Heterozygous plus homozygous carriers of factor V 
Leiden had a 2.2-fold increased risk of a first VT (Table 2, 95% CI 1.2-3.9), 
compared with participants who did not carry factor V Leiden. Factor V Leiden was 
present in 19 of 162 patients with DVT (11.7%) and 15 of 232 patients with PE 
with or without DVT (6.5%), leading to odds ratios of 3.0 for DVT (95% CI: 1.5-
6.0), and 1.4 for PE (95% CI: 0.7-2.9). The OR for provoked VT was slightly higher 
than the OR for unprovoked VT with factor V Leiden (OR 1.6, 95% CI 0.7-3.7 for 
provoked VT and OR 2.4, 95% CI 1.2-4.5 for unprovoked VT). Nine patients 
(2.3%) and seven controls (1.6%) were heterozygous carriers of the prothrombin 
G20210A mutation, and none were homozygous. This led to an OR for prothrombin 
G20210A mutation of 1.4 (95% CI 0.5-3.9). The OR for unprovoked VT with 
prothrombin G20210A mutation was 1.2 (95% CI 0.3-4.9) while a similar result 
was observed for provoked VT (OR 1.5, 95% CI 0.5-4.7). 231 (61.4%) patients 
and 232 controls (55.8%) had blood group non-O, resulting in an OR of 1.3 (95% 
CI 1.0-1.8) for blood group non-O. Blood group non-O was not associated with the 
risk of provoked VT (OR 1.0, 95% CI 0.7-1.5), whereas the risk of unprovoked VT 
was 1.5-fold increased (95% CI 1.1-2.1).   
We studied the combined effect of ABO blood group and the presence of either 
factor V Leiden or prothrombin G20210A mutation, with wildtype carriers of factor 
V Leiden and prothrombin G20210A mutation with blood group O as the reference 
category. Individuals carrying either prothrombotic variant and blood group O had 
a 2.3-fold increased risk of VT (95% CI 0.9-5.9) and wildtype carriers of factor V 
Leiden and prothrombin G20210A mutation with blood group non-O had a 1.3-fold 
increased risk of VT (95% CI 1.0-1.8). Those with both blood group non-O and a 
prothrombotic variant had a similar risk as those with blood group O and a 




Family history and risk of VT 
Family history of VT in a first degree relative was positive for 97 patients (24.2%) 
and 54 controls (12.5%). Individuals with a positive family history of VT had a 
more than 2.1-fold increased risk of VT compared with individuals without a 
positive family history of VT (95% CI 1.5-3.1). The association was similar when 
subjects who did not know their family history were excluded from the analysis 
(OR 2.2, 95% CI 1.5-3.2). The risk of both provoked and unprovoked VT was 
increased in the presence of a positive family history: OR provoked VT 1.7 (95% CI 
1.0-2.8); OR unprovoked VT 2.4 (95% CI 1.6-3.6). The risk of VT was not 
increased when only family members who had VT before the age of 50 years were 
considered positive (OR 0.9, 95% CI 0.5-1.6). The number of affected relatives 
was also not associated with the risk of VT; having more than 1 positive family 
member versus only 1 positive family member resulted in an OR of 0.8 (OR 0.8, 












































   
   




















   














































































































































































































































































































































   
   





















   
































































































































































To assess whether a positive family history was mainly determined by the presence 
of the factor V Leiden or the prothrombin G20210A mutations, we studied the 
association between a family history of thrombosis and these prothrombotic 
variants. Out of 97 patients with a positive family history, only 11 carried factor V 
Leiden or prothrombin G20210A mutation, yielding a positive predictive value of 
positive family history for factor V Leiden or prothrombin G20210A mutation of 
11%. When including non-O blood group to the analyses, out of 93 patients with a 
positive family history, 59 carried factor V Leiden, prothrombin G20210A mutation, 
or non-O blood group. This results in a positive predictive value of positive family 
history for factor V Leiden, prothrombin G20210A mutation or non-O blood group 
of 63%.  
In table 4 the associations of the combined risks of a positive family history of VT 
and carrying the factor V Leiden or the prothrombin G20210A mutation are shown. 
Excluding those who carried a prothrombotic variant, did not change the risk 
estimate of a positive family history: OR 2.1 (95% CI 1.4-3.1). Individuals with a 
positive family history of VT who also carried either a prothrombotic variant had a 
high risk of VT (OR 7.6, 95% CI 1.6-35.7). The PAR for factor V Leiden was 4.7%, 
for prothrombin G20210A mutation 0.7%, for non-O blood group 14.2%, and for a 













































































   
   




















   




































































































































































In this population-based case-control study of 832 individuals, we show that factor 
V Leiden, the prothrombin G20210A mutation, and non-O blood group are risk 
factors for VT in the elderly (>70 years) as they are in younger individuals, 
increasing the risk of VT 2.2-, 1.4-, and 1.3-fold respectively. Furthermore, a 
positive family history of VT doubled the risk of VT, regardless of the number of 
affected family members and their age of onset. The highest risk of VT was found 
in individuals who had both a positive family history and were carriers of one of 
the two prothrombotic variants. Among the genetic factors analysed, non-O blood 
group had the highest PAR for VT and the prothrombin mutation the lowest.  
Factor V Leiden and prothrombin G20210A mutation are well established risk 
factors for VT in young and middle-aged individuals. The risk is four- to sevenfold 
increased for factor V Leiden carriers and two- to threefold increased for the 
prothrombin G20210A.[3, 4, 19, 20] Our results indicate that factor V Leiden and 
prothrombin G20210A remain associated with the risk of VT in older age, as 
previously reported in several large studies [4, 20-22] and a small subgroup 
analysis.[23]  
Compared with blood group O, non-O individuals had a 1.3-fold increased risk of 
VT. The increased risk can be partly explained by higher levels of FVIII and von 
Willebrand Factor in ABO blood group.[24, 25] High FVIII levels are associated 
with a lowered responsiveness to activated protein C. In carriers of factor V Leiden, 
this association is strengthened as observed in previous studies, which explains the 
interaction between non-O blood group and factor V Leiden.[24, 26]  
We observed that the positive predictive value of family history of VT for a genetic 
risk factor for VT was low, as was also indicated in previous studies.[10, 13, 27, 
28] This may indicate that unknown or unmeasured genetic risk factors are 
present in individuals with a positive family history. Taken together with our 




among participants who were not carriers of factor V Leiden and prothrombin 
G20210A mutations, results support a strong hypothesis that unknown genetic 
factors or familial factors that are not genetic play a substantial role in VT 
aetiology.[29, 30]  
The risk of VT was highest in the presence of multiple genetic risk factors, 
illustrating the multicausal character of VT[1], which remains so in the elderly. The 
results are in line with studies reporting that heterozygous factor V Leiden and 
prothrombin G20210A mutation are relatively weak risk factors for VT, unless 
another genetic or acquired risk factor is present.[31] We observed lower relative 
risks for VT for genetic factors here compared to other studies in younger people. 
There are several reasons relative risks for any risk factor might be lower in the 
elderly than in middle-aged individuals. Attrition of susceptibles, such that 
susceptible individuals with factor V Leiden or prothrombin G20210A mutations are 
more likely to develop VT earlier in life, would result in lower relative risks at an 
older age. The higher absolute risk of VT in the elderly lead to smaller relative 
effects of individual risk factors than in middle-aged individuals. In other words, 
whereas the relative risks are smaller than in the young, absolute risk differences 
for carriers versus non-carriers are substantial, given the high baseline risk in the 
elderly. Specifically, the PAR of non-O blood group of 14.2% in our study was 
lower than reported in a previous study conducted in a younger population 
(25.0%), and the PAR of factor V Leiden in our study was higher (4.7% compared 
to 2.8%).[7] Given their high prevalence, the PARs of both non-O blood group and 
a positive family history of VT (12.7%) were high.  
The strengths of our study includes the specific focus on individuals aged 70 years 
and older. Home visits were performed in order to achieve a high participation rate 
(participation rate: cases 69%, controls 73%). It is one of the few studies on VT 
risk that evaluated family history of VT in the elderly.  
Our study also has limitations. Controls with a positive family history of VT might 




positive family history of VT. However, this selection bias would result in an 
underestimation of the true association. Patients with VT might be more likely to 
be aware of their family history after they have a VT, which could bias results 
toward overestimation of the association. This might have been mitigated by the 
short duration of time between the VT and the study interview (median was 5 
weeks for patients). Moreover, as in any case-control study, recall bias might have 
occurred when obtaining information on risk factors used for the classification into 
provoked and unprovoked VT and family history. However, by using standardized 
interviews performed by trained personnel for both cases and controls, the risk of 
recall bias was minimized. 
Our results may have clinical implications. A positive family history of VT doubled 
the risk of VT in the elderly. In clinical practice this information is easy to obtain, 
however it is not implemented in clinical decision rules of VT risk. In the elderly 
these clinical decision rules show a high failure rate.[32] Potentially, obtaining 
information on family history of VT in individuals aged 70 years or older could 
improve prediction of VT in the elderly.[33] Future studies should evaluate whether 
diagnostic tools improve when implementing family history.  
In conclusion, this study demonstrated that factor V Leiden, prothrombin G20210A 
mutation, non-O blood group and a positive family history for VT are risk factors 
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Venous thrombosis is common in older age, with an incidence of 0.5–1% per year 
in those aged >70 years. Stasis of blood flow is an important contributor to the 
development of thrombosis and may be due to venous insufficiency in the legs. 
The risk of thrombosis associated with clinical features of venous insufficiency, i.e., 
varicose veins, leg ulcers and leg oedema, obtained with a standardized interview 
was assessed in the Age and Thrombosis Acquired and Genetic risk factors in the 
Elderly (AT-AGE) study. The AT-AGE study is a case–control study in individuals 
aged 70 years and older (401 cases with a first-time venous thrombosis and 431 
control subjects). We calculated odds ratios (ORs) and corresponding 95% 
confidence intervals (CI) adjusted for age, sex and study centre. Varicose veins 
and leg ulcer were associated with a 1.6-fold (95% CI 1.2–2.3) and 3.3-fold 
increased risk of thrombosis (95% CI 1.6–6.7), respectively, while the risk was 
increased 3.0-fold (95% CI 2.1–4.5) in the presence of leg oedema. The risk of 
thrombosis was highest when all three risk factors occurred simultaneously (OR: 
10.5; 95% CI 1.3–86.1). In conclusion, clinical features of venous insufficiency, 
i.e., varicose veins, leg ulcers and leg oedema, are risk factors for venous 





The incidence of venous thrombosis increases steeply with age, with an incidence 
of 0.5–1% per year in people aged over 70 years (Naess et al, 2007). More than 
60% of all thrombotic events occur in this age group (Rosendaal et al, 2007). 
Stasis of blood flow is, together with hypercoagulability and endothelial injury, an 
important contributor to the development of venous thrombosis according to 
Virchow’s triad (Virchow, 1856). Stasis can occur due to external pressure on the 
vein during, e.g., prolonged immobilization or pregnancy, or due to venous 
insufficiency in the legs. Venous insufficiency comprises a spectrum of clinical 
features, including varicose veins, venous ulcer and leg oedema (Duran et al, 
2000; Mustoe, 2004; Langer et al, 2005). Like venous thrombosis, the prevalence 
of venous insufficiency increases steeply with age (Ruckley et al, 2002; Carpentier 
et al, 2004; Beebe-Dimmer et al, 2005). There is limited information on the role of 
venous insufficiency in the development of venous thrombosis. In young and 
middle-aged individuals, varicose veins strongly predispose to superficial 
thrombosis and are also associated with an increased risk of deep vein thrombosis 
(Heit et al, 2000; Marchiori et al,2006; Decousus et al, 2012). The contribution of 
venous insufficiency to the incidence of venous thrombosis in the older population 
is unknown. The aim of this study was to investigate whether clinical features of 
venous insufficiency, defined as a history of varicose veins, leg ulcer or leg 
oedema, are risk factors for venous thrombosis in individuals aged 70 years and 
older. In addition, the contribution of these factors to the incidence of deep venous 
thrombosis was evaluated.  
Methods  
Participants 
The Age and Thrombosis Acquired and Genetic risk factors in the Elderly (AT-AGE) 
study is a two-centre population-based case–control study. The study has been 
described in detail previously (Engbers et al , 2014). In brief, between 2008 and 




thrombosis in the leg (DVT) or a pulmonary embolism (PE) were identified in 
defined geographical areas in Leiden, the Netherlands and Burlington, Vermont, 
USA. In Leiden, cases were identified in two anti-coagulation clinics (Leiden and 
Haarlem). In Vermont, cases resided in a 45 km radius of Burlington, and were 
diagnosed at the University of Vermont Medical Center in Burlington, the only 
diagnostic centre in that area.  
Presence of DVT required positive compression ultrasonography or Doppler 
ultrasound. PE was considered definite in case of a positive spiral computerized 
tomographic or high probability ventilation-perfusion lung scan. We defined venous 
thrombosis as DVT alone or PE with or without a proven DVT by ultra-sound (PE ± 
DVT). We invited the population-based control subjects randomly from primary 
care practices in the same geographical areas (five in Leiden and four in Vermont). 
We defined the index date for the cases as the date of diagnosis of the thrombotic 
event. For control subjects the index date was the date of completing the interview 
at home. Individuals with active malignancy, defined as diagnosis of cancer, or 
chemotherapy or radiation therapy for cancer within 6 months before the index 
date, and those with severe psychiatric or cognitive disorders were excluded from 
participation, as were individuals who self-reported previous DVT or PE within the 
past 10 years. Of 1187 identified cases, 689 (58%) were eligible. In Leiden, 398 
(71%) of the 561 invited cases and 321 (76%) of the 422 invited control subjects 
participated. In Burlington, 128 cases were invited and 75 (59%) participated, 
while 140(67%) of the 209 invited control subjects participated. Detailed 
information about the reasons for exclusion or not participating in the study can be 
found elsewhere (Engbers et al, 2014). All participants provided written informed 
consent. The study was approved by the Medical Ethical Committee of the Leiden 
University Medical Centre and by the Committee on Human Research of the 







Trained personnel performed an extensive interview during a home visit. For the 
analyses on the aetiology of venous thrombosis we included the cases and control 
subjects without a history of venous thrombosis and who completed the interview 
at home (401 cases and 431 control subjects). For the cases, the median duration 
between the index date and the home visit was 5 weeks (range 1–44 weeks), 75% 
were visited within 7 weeks and 90% were visited within10 weeks. The interview 
obtained information about the presence of well-known risk factors, such as recent 
hospitalization, surgery and fracture and a blood sample or buccal swab was 
collected (Engbers et al, 2014). The participants were asked about any prior 
history of varicose veins or leg ulcer or whether they had a history of leg oedema 
that lasted until at least the 3 months before the index date. Leg oedema was 
classified by participants as ‘daily oedema’, ‘intermittent oedema’ or ‘no oedema’. 
The first version of the interview questionnaire for the control subjects did not 
include the question of oedema, as this was incorporated after this. For this 
reason, this data could not be reported for 24 control subjects. We used self-
assessed information on clinical features of venous insufficiency, a strategy that 
has been previously validated (Laurikka et al, 1995). In addition, cases were asked 
to provide self-assessed information on the type and duration (in days) of possible 
thrombotic complaints prior to the diagnosis of the thrombotic event. The 
thrombotic event was defined as provoked if, in the 3 months before the 
thrombosis, one of these conditions was positively identified: hospitalization, 
surgery, a fracture, plaster cast or splint use, a minor injury or immobilization in 
the home situation (Engbers et al, 2014). Physical measurements were performed 
including weight (measured with a calibrated scale) and height. Body mass index 
(BMI) was calculated by dividing bodyweight (kg) by squared height (m2).  
Statistical analysis 
To provide insight into the source population at the two study sites, we compared 




associations between potential confounders, i.e., sex and BMI and features of 
venous insufficiency in the complete control group. The risk of venous thrombosis 
associated with the presence of history of varicose veins, leg ulcer and leg oedema 
in the 3 months before the thrombosis was determined. We assessed a dose-
response relationship for oedema across groups of those with none, intermittent or 
daily oedema. The risk of thrombosis associated with the presence of one, two or 
three of the symptoms of venous insufficiency was assessed. Odds ratios (OR) and 
95% confidence intervals (CI) were calculated as an estimate of the relative risk of 
venous thrombosis. We used a multiple logistic regression model to calculate 
adjusted OR. All ORs reported here were adjusted for age (continuous), sex and 
study centre. Additionally we adjusted for BMI (continuous), smoking status and 
the presence of the F5 R506Q (factor V Leiden) or F2 (prothrombin)20210A 
mutation. Stratified analyses were performed by type of thrombosis (DVT and PE ± 
DVT) and the presence of provoking factors, i.e. provoked and unprovoked first 
venous thrombosis. We performed two analyses to address whether other causes 
of leg oedema than venous insufficiency explained our findings. Firstly, heart 
failure is associated with an increased risk of venous thrombosis and leg oedema 
can be present in individuals with heart failure (Breidthardt et al, 2012). To assess 
the risk of venous thrombosis associated with leg oedema as a symptom of venous 
insufficiency, we excluded participants with a self-reported history of heart failure. 
Secondly, to assess whether the presence of daily leg oedema might have been a 
(pre)clinical sign of the venous thrombosis (rather than due to venous 
insufficiency), we determined the risk of thrombosis associated with daily leg 
oedema in the individuals who reported a clinically asymptomatic event of venous 
thrombosis, e.g. individuals that did not reported any acute thrombotic complaints 
of the legs or lungs before the diagnosis. To assess the contribution of venous 
insufficiency to the incidence of venous thrombosis in this older population, we 
estimated the population attributable risk (PAR) of a history of varicose veins, leg 
ulcers and daily leg oedema and the number of these symptoms combined. The 
PAR was calculated as pd (OR - 1)/(OR), where pd is the prevalence of the risk 




(Bruzzi et al, 1985). All statistical analyses were performed using SPSS 20 for 
Windows (SPSS Inc, Chicago, IL, USA). 
Results 
Characteristics of the control subjects of the two AT-AGE study centres are shown 
in Table I. In both centres, one-third of the control subjects were 80 years or 
older. Median BMI was 25.9 kg/m2 (range 17.0–42.0 kg/m2) in Leiden, and 27.3 
kg/m2 (19.0–49.7 kg/m2) in Vermont. The prevalence of intermittent and daily leg 
oedema was similar at the two study centres, while the prevalence of varicose 
veins and leg ulcers was higher in Leiden than Vermont. Symptoms of venous 
insufficiency were associated with sex and BMI. Women more often had varicose 
veins and leg oedema than men (varicose veins: women 28.4%, men 14.4%; 
oedema: women 17.1%, men 7.1%). Leg ulceration was rare and more common 
in men (3.3%) than women (1.8%). Obese individuals more often had leg oedema 
and leg ulceration than normal weight individuals but this association was less 
clear for varicose veins (BMI > 30 kg/m2 compared with <25 kg/m2: oedema: 
38.3% vs. 16.1%, leg ulceration: 5.3% vs. 1.3%; varicose veins: 23.4% vs. 













Tabel I Characteristics of Control Subjects by study centre  
  Leiden (NL) Vermont (US) 
Control subjects, n 306 125 
Median Age (range), years 76 (70-94) 76 (70-96) 
    70-75 years, n (%) 
    75-80 years, n (%) 
    80-85 years, n (%)  









Men, n (%) 147 (48.0) 62 (49.6) 
Median BMI (kg/m2) (range)* 25.9 (17.0-42.0) 27.3 (19.0-49.7) 
Varicose veins, n (%) 73 (23.9) 20 (16.0) 
Leg ulcer, n (%)  10 (3.3) 1 (0.8) 
Leg oedema† 
    Never, n (%) 
    Intermittent, n (%) 










NL = the Netherlands; US = United States; n = number; BMI = body mass index 
*BMI: data missing for 8 controls  





Table II shows the risk of venous thrombosis associated with symptoms of venous 
insufficiency. Individuals with varicose veins had a 1.6-fold increased risk of venous 
thrombosis compared with individuals without varicose veins (OR 1.6; 95% CI 1.2–
2.3). A history of a leg ulcer was associated with a threefold increased risk of 
thrombosis (OR 3.3; 95%CI 1.6–6.7). Leg oedema during the 3 months before 
thrombosis (daily and intermittent oedema combined) was associated with a 
threefold (95% CI 2.1–4.5) increased risk of venous thrombosis compared with no 
oedema. There was a dose-response relationship of severity of oedema and the 
risk of venous thrombosis. Compared with individuals without oedema, individuals 
with intermittent oedema had a 1.6-fold increased risk of venous thrombosis (95% 
CI 1.0–2.5) whereas this risk was 3.1-fold increased for individuals with daily 
oedema (95% CI 2.1–4.5). The associations between the clinical features of 
venous insufficiency and thrombosis remained present after adjustment for BMI 
and smoking (Table II). Adjustment for the presence of the F5R506Q and F2 
20210A mutation showed similar risk estimates: varicose veins: OR 1.7 (95% CI 
1.3–2.4), leg ulcer: OR 3.4 (95% CI 1.7–6.8), leg oedema: OR 3.1 (95% CI 2.1–
4.6). Excluding individuals with heart failure (20 cases and 19 controls) did not 
change the risk associated with leg oedema, i.e., compared with no oedema, the 
risk of venous thrombosis was 1.5-fold increased for intermittent oedema (OR 1 .5, 
95% CI 1.0–2.3) and 3.2-fold increased for daily oedema (OR 3.2, 95% CI 2.1–
4.8).  
Information on the presence or absence of thrombotic complaints prior to the 
diagnosis of venous thrombosis was available for 376 cases (93.8%). Of the cases, 
322 (85.6%) reported leg complaints specifically attributable to the subsequent 
diagnosis of venous thrombosis, whereas 54 (14.4%) did not. Among the latter, 
daily leg oedema was associated with a 2.6-fold (95% CI 1.3–5.2) increased risk of 
venous thrombosis compared with no leg oedema. Of the cases, 219 (54.6%) had 
an unprovoked venous thrombotic event. Varicose veins were associated with a 
1.3-fold (95% CI 0.9–2.0) increased risk of an unprovoked venous thrombosis. 




CI 2.1–5.3) for leg oedema (daily and intermittent oedema combined). For 
provoked venous thrombosis we found a 2.0-fold (95% CI 1.4–2.9) increased risk 
for varicose veins and a 3.4-fold increased risk (95% CI 1.5–7.4) for leg ulcer. Leg 
oedema was associated with a 2.8-fold (95% CI 1.7–4.4) increased risk of 
provoked thrombosis.  
To assess the association of severity of venous insufficiency with risk of venous 
thrombosis, we determined the risk associated with number of venous insufficiency 
symptoms. The presence of one, two or three of the clinical features gradually 
increased the risk of thrombosis, with the highest risk of venous thrombosis 
associated with the presence of all three clinical features compared with none of 
the features (OR:10.5; 95% CI 1.3–86.8) (Table III). Of the cases, 166 (41%) 
were diagnosed with DVT only and 235 (59%) were diagnosed with PE ± DVT. The 
associations of venous insufficiency features with thrombosis risk were similar for 
both types of thrombosis except that the association of leg ulcer with DVT 
appeared stronger than the association with PE ± DVT (Table IV).  
The PAR of the three manifestations of venous insufficiency was 12.3% for 
varicose veins, 6.0% for a leg ulcer and 22.0% for the presence of leg oedema. 
The PAR of presence of two symptoms of venous insufficiency was 22.7% and for 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In this population-based case–control study among individuals aged 70 and older, 
symptoms of venous insufficiency, i.e., a history of varicose veins, leg ulcer and 
oedema, increased the risk of venous thrombosis (both DVT and PE), with ORs 
ranging from 1.6 to 3.0. The risk of venous thrombosis increased with severity of 
the venous insufficiency, defined as the number of clinical features. The risk was 
highest in individuals with all three clinical features combined (OR 10.5), although 
presence of all three features was uncommon.  
In agreement with the literature, venous insufficiency was common, both in the 
cases and control subjects (Carpentier et al, 2004), leading to a high PAR of 
venous thrombosis associated with varicose veins and leg oedema. Adjustments 
for potential confounders did not influence the finding that clinical features of 
venous insufficiency are risk factors for thrombosis. Moreover, restricting the 
analysis to cases with unprovoked venous thrombosis demonstrated that the risks 
associated with symptoms of venous insufficiency are not explained by the 
presence of other major risk factors of thrombosis in the older population, such as 
recent hospitalization and surgery (Engbers et al, 2014).  
Some, but not all, studies have reported that varicose veins are associated with an 
increased risk of DVT and PE in the young and middle-aged (Goldhaber et al, 
1983; Heit et al, 2000; Huerta et al, 2007; Muller-Buhl et al, 2012; Zoller et al, 
2014). Heit et al (2000) demonstrated a fourfold increased risk of venous 
thrombosis associated with varicose veins in middle-age up to age 60 years, but in 
contrast to the current study, they observed no increased risk in those 70 years 
and older. This difference in findings may be due to a difference in data collection: 
Heit et al (2000) used medical records to assess chronic venous insufficiency, 
whereas we collected data on clinical features of venous insufficiency by an 
interview. Mild disorders, such as varicose veins, may be documented less often in 
medical records of older individuals, particularly when other co-morbidities are 




To our knowledge, presence of leg oedema due to chronic venous insufficiency has 
not been investigated as a risk factor for venous thrombosis in the older 
population. Leg oedema could be a pre-clinical sign of thrombosis; however, we 
showed that, among individuals who did not report any thrombotic complaints 
prior to the diagnosis of venous thrombosis, leg oedema was still associated with a 
more than twofold increased risk of thrombosis compared with no oedema. This 
indicates that our findings are probably not explained by leg oedema being a 
symptom of deep vein thrombosis. Heart failure, as an underlying cause of leg 
oedema, may explain the association between leg oedema and venous thrombosis; 
however in our study excluding the individuals with heart failure did not change 
the results. We hypothesize several mechanisms by which venous insufficiency 
may increase the risk of venous thrombosis. Firstly, varicose veins, due to 
dysfunction of the venous valves, lead to low sheer stress in the veins and reduced 
blood flow, which subsequently lead to a pro-thrombotic state (Brooks et al, 2009; 
Atta, 2012). It has been hypothesized that damage to the valves results in 
hypoxia, especially in the valve pockets, which promotes thrombus formation at 
this location (Van Langevelde et al, 2010). Secondly, inflammation may play an 
important role. Leg oedema as a result of long-term venous insufficiency could 
lead to mediator release and inflammation in the veins (Bovill & van der Vliet, 
2011; Cushman et al, 2014). Leg ulceration is also associated with local 
inflammatory processes (Chen & Rogers, 2007). We hypothesize that this 
inflammatory state could initiate local thrombus formation within the leg veins. A 
leg ulcer is the most severe expression of venous insufficiency of the three clinical 
features that we assessed in this study (Porter & Moneta, 1995). In concordance 
with this, among the venous insufficiency features evaluated, the strongest 
association with thrombosis risk was found for leg ulcer. Finally, it has been 
suggested that venous insufficiency in the absence of a prior history of DVT may 
be due in part to prior undiagnosed DVT, which might increase the risk of future 




In the AT-AGE study we achieved high participation rates, which is challenging in 
older people (Bugeja et al,1997). As venous thrombosis and venous insufficiency 
are both associated with immobility, performing home visits to both cases and 
control subjects minimized selection bias due to selection of only mobile older 
individuals. Moreover, by performing interviews we were able to determine risk 
factors that are not reported regularly in medical reports. Limitations of the current 
study require consideration. Recall bias may have affected our results, although we 
minimized this by performing standardized interviews, in both the cases and the 
control subjects. Referral bias could play a role in our results, e.g., if individuals 
with varicose veins are more likely to be referred for ultrasound of the legs, 
resulting in an overestimation of the risks. However, as we also found an increased 
risk for PE with clinical features of venous insufficiency, we do not expect this to be 
a major influence. As the clinical features of venous insufficiency were all self-
reported, over- or under-reporting of the clinical features cannot be ruled out. We 
would anticipate that the presence of any misclassification would be non-
differential in the cases and the control subjects, which may have led to an 
underestimation of the risks. Ideally, clinical examination of the legs before the 
thrombotic event should have been performed. The AT-AGE study is a 
predominantly Caucasian study, thus we were not able to address racial 
differences in the associations.  
In conclusion, clinical features of venous insufficiency(varicose veins, leg oedema, 
leg ulcer) were found to be risk factors for venous thrombosis in this older 
population. This gives further insight into the aetiology of venous thrombosis in 
older people. Physicians may be more alert for thrombosis when one of the clinical 
features of venous insufficiency is present as these contribute to the burden of 
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As early as 1851 Virchow observed a slight left-sided predominance of deep vein 
thrombosis. He explained this observation by relating it to compression of the left 
common iliac vein by the right common iliac artery.[1]In the 1950s researchers 
May and Thurner[2] found that the right iliac artery compressed the left common 
iliac vein against the fifth lumbar vertebra in 22% of 430 cadavers and that venous 
webs or spurs had formed at the point where the artery crosses the vein. It was 
hypothesised that venous spurs might predispose to deep vein thrombosis (DVT) 
at this location. When DVT occurs during pregnancy, the shift to the left becomes 
extreme (five times more often than right sided), and this might also be 
attributable to the compression of the left common iliac vein by the pregnant 
uterus.[3] However, in the middle aged non-pregnant population, obesity does not 
appear to cause left common iliac vein compression since there is no left-sided 
predominance for DVT associated with obesity.[4]  
Ageing might affect the veins, vessel wall, and venous valves,[5, 6] and might lead 
to a change in the pattern of venous thrombi distribution. As the incidence of 
venous thrombosis increases markedly in the elderly,[7] mapping the distribution 
of venous thrombi in this age group is important. Therefore, the aim of our study 
was to examine how venous thrombi are anatomically distributed in patients aged 
70 years and older.  
Methods 
Study design and population 
The Age and Thrombosis: Acquired and Genetic risk factors in the Elderly (AT-AGE) 
study is a two-center population-based case-control study performed in Leiden and 
Haarlem, the Netherlands and Burlington, VT, the United States. The design of the 
AT-AGE has been described in detail previously.[8] All consecutive patients aged 
70 years and older with deep venous thrombosis in the leg (DVT) or pulmonary 




from the anticoagulation clinic in Haarlem and Leiden and in Vermont from the 
Vascular Laboratory and the Radiology department the University of Vermont 
Medical Center (Burlington, Vermont, United States). Individuals with an active 
malignancy, chemotherapy, or radiation therapy for cancer in 6 months prior to the 
thrombotic event, individuals with severe psychiatric or cognitive disorders, and 
individuals who self-reported a previous DVT or PE, were excluded. All eligible 
cases who agreed to participate, were visited at home to perform an extensive 
structured interview. The index date was defined as the date of diagnosis of the 
thrombosis. The study was approved by the Medical Ethical Committee of the 
Leiden University Medical Center and by the Committee of Human Research of the 
University of Vermont. All participants provided written informed consent. 
Outcome assessment 
Patients were identified from the anticoagulation clinics in Haarlem and Leiden and 
from the Vascular Laboratory and the Radiology department of the University of 
Vermont Medical Center. Presence of DVT required positive compression 
ultrasonography or Doppler ultrasound. PE was considered definite in case of a 
positive spiral computerized tomographic or high probability ventilation- perfusion 
lung scan. For the patients included in the Netherlands, discharge letters from 
treating physicians were obtained for 309 patients out of a total of 341 patients 
(90.6%). Information on affected veins was based on data from these discharge 
letters. For the other patients as well as for the patients included in Vermont, self-
reported information on type of thrombosis (deep vein thrombosis or pulmonary 
embolism) and the side of the deep venous thrombosis of the leg was obtained 
from the interview. In Vermont no information on affected veins was available.  
Study definitions 
The proportions of left- and right-sided DVT were calculated. Descriptive statistics 
were used to analyse the anatomical distribution of venous thrombi, with the 




popliteal veins, and distal location defined as involvement of calf, tibial or 
gastrocnemius veins. Provoked DVT was defined as DVT within 3 months after 
hospitalisation, fracture, plaster cast, splint, or transient immobility at home ≥4 
successive days. Body mass index (BMI) was calculated by dividing body weight 
(kg) by squared height (m2). IBM SPSS Statistics 20.0 for Windows (SPSS Inc, 
Chicago, Ill) was used for data analysis.  
Results and discussion 
401 patients with a first venous thrombosis were included, of whom 166 (41.4%) 
patients had DVT only, 22 (5.5%) DVT with PE and 213 (53.1%) PE without DVT. 
Of the 188 patients with a DVT of the lower extremities, 101 patients had a left-
sided DVT, 4 patients had a bilateral DVT and for one patient the side of DVT was 
unknown (Table 1). The predominance of left-sided DVT did not differ between 
obese individuals (53.5% left) and non-obese individuals (59.4% left), or by 
whether the DVT was provoked (51.8% left) or idiopathic (56.7% left). There was 
a clear left-sided predominance within women (61.5% left, 38.5% right), while no 
clear predominance was observed in men (48.3% left, 51.7% right).  
The most often affected vein was the popliteal vein (41%), followed by the femoral 
vein (39%), calf veins (23%), iliac vein (9%) and inferior vena cava (1%). In men, 
the popliteal and femoral veins were affected slightly more often than in women: 
11% for the popliteal and the femoral vein in men compared with 8% for the 
popliteal vein and 7% for the femoral vein in women. There were 44 patients 
(23%) with involvement of both the popliteal vein and femoral vein. Only 18 




Table 1 Distribution of risk factors for DVT in patients with left- and right-sided DVT 
 Left leg DVT* Right leg DVT* 
DVT, n (%, 95% CI) 101 (55.2, 48.0-62.4) 82 (44.8, 37.6-52.0) 
Female sex, n (%) 59 (58.4) 37 (45.1) 
Age, mean (95% CI) 78.8 (77.6-79.9) 78.7 (77.4-79.9) 
BMI, mean (95% CI) 27.7 (26.7-28.7) 27.2 (26.3-28.2) 
BMI ≥30, n† (%) 23 (23.2) 20 (27.8) 
BMI <30, n (%) 76 (76.8) 52 (72.2) 
Provoking factors, n (%) 29 (28.7) 27 (32.9) 
     Fracture, n left/right 4/1 2/4 
     Plaster cast, n left/right 3/1 0/2 
Proximal vein involvement, n (%) 57 (56.4) 50 (61.0) 
Distal vein involvement, n (%) 26 (25.7) 15 (18.3) 
 
*Bilateral DVT’s were excluded 
†BMI missing  for 12 individuals 
The results of our study are consistent with those of previous studies conducted in 
younger individuals showing a predominance of left-sided DVT.[4, 9, 10] As in 
other studies, the popliteal and femoral veins were the most prevalent sites of 
thrombi.[11, 12] In our study, single occlusion of veins other than the calf vein 
was not uncommon (42 individuals, 22%). This was in contrast to a finding in 
another study, in which single occlusion of veins was unusual.[11] A limitation of 
our study is that we have not quantified abdominal fat with imaging techniques.  
We conclude that in the elderly with DVT, there is a left-sided predominance of 
DVT and this observation did not vary between sexes, by age, BMI, provoking 
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Background Increasing age is the strongest risk factor for venous thrombosis (VT). 
Increasing age has been related to a thickening of the venous valves and a 
decreased valvular function. The association between valve thickness and the risk 
of VT is not known. 
Objectives To assess the association between increased valve thickness and valve 
closure time (VCT) and the risk of VT.  
Methods Analyses were performed in the BATAVIA study, including 70 cases aged 
70+ with a first VT and 96 controls. We performed an ultrasound examination of 
the valves in the popliteal veins. The valves were imaged with a 9 MHz linear probe 
using B-mode ultrasonography. VCT was measured as an indicator for valve 
function using an automatic inflatable cuff. To estimate the risk of VT, valve 
thickness was dichotomized at the 90th percentile as measured in controls and VCT 
was dichotomized at 1 s. 
Results Mean valve thickness of controls was similar in the left (0.36 mm, 95%CI 
0.34-0.37) and right (0.36 mm, 95%CI 0.35-0.38) leg. In 45 cases a valve was 
observed in the contralateral leg with a mean valve thickness of 0.39 mm (95%CI 
0.36-0.42). Cases had an increased valve thickness compared with controls: mean 
difference 0.028 mm (95%CI 0.001-0.055). Valve thickness >90th percentile 
increased the risk of VT 2.9-fold. Mean VCT in controls was 0.38s, in contralateral 
leg of cases 0.58s. VCT>1 s increased the risk of VT 2.8-fold (95%CI 0.8-10.4). 
Conclusions Risk of VT was associated with increased valve thickness and valvular 





Several studies indicate that the majority of venous thrombi originate in the valve 
pockets. The valve pocket is the space between valve cusp and the vessel wall. In 
the deeper parts of the valve pockets, flow circulates at low velocity, creating two 
counter-rotating vortices[1], and becomes increasingly hypoxic.[2] Hypoxia leads 
to endothelial damage, creating a hypercoagulable environment.[3, 4]  
Age-related changes of venous valves have been described in several ex vivo 
studies and in one in vivo study. The ex vivo studies demonstrated a thickening of 
the valves with age in renal[5] and in femoral veins[6]. The thickening of the 
valves in these studies was shown to be the result of atrophy of muscle fibers, 
hypertrophy of elastic fibers, and an increased number of collagen fiber bundles. 
We previously demonstrated that in vivo visualization of venous valves and 
measurement of valve thickness by ultrasound is possible and reproducible. It was 
shown that ageing is associated with thicker valves, as measured by ultrasound.[7] 
Valvular reflux can proceed from venous thrombosis (VT), leading to the post-
thrombotic syndrome (PTS).[8, 9] However, reflux can also lead to an increased 
risk of VT by increasing stasis and subsequent local hypoxia, thereby contributing 
to a hypercoagulable environment.  
VT is rare in young individuals (<1 per 10 000 per year) but increases to 
approximately 1% per year in old age.[10] As the incidence of VT increases 
strongly with age and the worldwide population of the elderly grows,[11] the focus 
on the aetiology and prevention of disease in the elderly becomes more relevant. 
Ageing of venous valves, i.e. thickening of the valves and a decrease in valvular 
function has not been studied in relation to VT.  
Therefore, the aim of our study was threefold: 1) to study the association between 
thickened valves in the popliteal vein and the risk of VT; 2) to study the association 








The Biology of Ageing and Thrombosis: Appraisal of Valve thickness and function, 
an In Vivo Assessment (BATAVIA) Study is a population-based case-control study in 
Leiden, the Netherlands. Patients with deep venous thrombosis of the leg with or 
without pulmonary embolism, who were included in the AT AGE study, a case-
control study on risk factors for venous thrombosis in the elderly, were invited to 
participate in the BATAVIA study.[12] In the AT AGE study, consecutive elderly 
patients (older than 70 years) who had a first deep vein thrombosis (DVT) with or 
without pulmonary embolism (PE) from June 2008 to July 2011 were identified at 
two regional Anticoagulation Clinics in Leiden and Haarlem as part of a large 
multicentre study on risk factors for venous thrombosis in the elderly. Diagnosis of 
DVT was objectively confirmed by compression ultrasonography or duplex 
ultrasound. Information on affected veins was based on the discharge letters 
collected from hospitals. Control subjects were identified in the same geographic 
area as the cases. Control subjects were randomly selected from five primary care 
practices in Leiden. Individuals with a history of VT, present or recent malignant 
disease (i.e. diagnosis of cancer, chemotherapy or radiation therapy for cancer 
within six months of VT diagnosis or date of telephone call for the control 
subjects), severe psychiatric or cognitive disorder were excluded. For the BATAVIA 
study, for practical reasons, individuals living in nursing homes were excluded.  
Of the 160 identified cases from the ATE AGE study, 104 were eligible to 
participate in the BATAVIA study. To increase the sample size, additional patients 
with same inclusion and exclusion criteria were selected from the anticoagulation 
clinic in Leiden. Patients with a first DVT between August 2011 and July 2013 
(n=61) were identified. Of these 61 newly identified cases, 32 were eligible. Of a 




study (Figure 1). Reasons for not being invited were the following: 29 (34%) died 
before inclusion in the BATAVIA study was possible, 28 (11%) had developed a 
cognitive or psychiatric disorder or were currently living in nursing homes, 2 (2%) 
had active malignancy, and 30 (35%) had a prior history of VT. Of the 289 
identified control subjects, 215 (74%) could be invited and of the 215 invited 
control subjects, 97 (45%) participated. Of those who could not be invited, 52 
(70%) died before inclusion was possible, 15 (20%) had developed a cognitive or 
psychiatric disorder and were currently living in nursing homes, 2 (3%) had an 
active malignancy, and 5 (7%) had a history of VT. In the end 70 cases and 96 
control subjects participated in our study.   
All participants gave written informed consent. The study was approved by the 
Medical Ethics committee of the Leiden University Medical Center, Leiden, the 
Netherlands.  
Data collection 
All identified cases and control subjects received an invitation letter by mail, 
followed by a telephone call to discuss participation. Home visits for an extensive 
structured interview and LUMC visits for the ultrasound examinations were 
scheduled for all eligible cases and control subjects.  
The interview included questions on presence of varicose veins, use of plaster cast 
of lower extremities, and surgery of lower extremities both at the time of the index 
date and ever in their lives. The index date was defined as the date of the 
diagnosis of the VT for the cases and the date of the interview for the control 
subjects. Physical measurements were performed including weight and height. 
Body mass index (BMI) was calculated by dividing body weight (kg) by height 
squared (m2). 
Ultrasounds examinations were performed using an adjustable examination table, 
set to an inclination of 45° anti-Trendelenburg, as described previously.[7] The 




participants were not able to stand on the examination table (n=18), they were 
asked to sit on the table, legs stretched. Imaging of the valves of the popliteal vein 
in both legs was done using 9-MHz linear probe using B-mode ultrasonography 
(z.one; Zonare® Medical Systems, Inc., Mountain View, CA, USA). In both legs, the 
transducer was first placed transversely in the popliteal fossa. Compression of the 
popliteal vein was done to confirm the absence of thrombosis. Then, the 
transducer was placed longitudinally following the vein over 10 to 12 centimeters in 
search of valves. When valves were visualized, multiple images were saved for 
offline processing. 
Valvular function was assessed using an automatic inflatable cuff (Hokanson rapid 
cuff inflator, Bellevue, Wash). Time of reversed flow following valve closure was 
measured. We achieved valve closure by applying standardized calf compression of 
100 mm Hg with the inflatable cuff. Valve closure time (VCT) is a validated method 
to discriminate between normal and incompetent venous valves.[13]  
Valve thickness was measured offline using a dedicated in-house developed 
software program (VesselMass, Leiden University Medical Center, Leiden) [14]. For 
every participant, the presence or absence of valves in both legs was documented. 
Images of valve leaflets which had the best visibility, and sharpest contours and a 
clear attachment to the venous vessel wall, i.e., the so called valvular agger, were 
selected for further measurements. To standardize the measurement of the valve 
leaflet and because the attachment of the valve leaflet to the vessel wall is not 
always visible in the imaging procedure, we used a fixed measuring distance of the 
valve starting 2 mm from the vessel wall using the method previously described by 
van Langevelde et al. Figure 2 shows a schematic drawing of the valve 
measurement.  
All ultrasonography examinations and offline measurements were done by one of 
the researchers (AK). The ultrasonography images were stored anonymously, and 
therefore the measurements were done without prior knowledge on whether 




Blood samples were drawn into vacuum tubes containing 0.1-volume 0.106-mol/L 
trisodium citrate or when no blood sample could be drawn a buccal swab was 
collected. The blood sample was separated into plasma and cells through 
centrifugation. DNA analysis for the factor V Leiden mutation (rs6025) and the 
prothrombin G20210A mutation (rs1799963) was performed using a combined 
polymerase chain reaction method with the TaqMan assay. The 20146G/- 
(rs8176719), 21463C/G (rs7853989), 21867A/G (rs8176749), and 21996C/- 
(rs8176750) blood group polymorphisms were determined by a 5’nuclease assay 
(Taqman; Applied Biosystems, Foster City, CA, USA) using a PCR reaction mix 
(Taqman Genotyping Master Mix, Applied Biosystems) and an allele-specific 
fluorescent probe equipped with a minor groove binding moiety (Applied 
Biosystems). 
Statistical analysis 
Determinants of valve thickness were assessed in the control subjects as reflecting 
the general population of this age. Determinants were established by comparing 
means and using linear regression. Mean thickness of the imaged valve in the left 
and right leg in the control subjects was calculated separately. Since there was no 
difference between the left and right leg (mean difference 0.009 mm, 95% CI -
0.016-0.034), we combined the thickness from both legs and calculated a mean 
valve thickness in control subjects. The mean value of both legs was used in all 
further analyses. 
We studied the association between VT and an increased valve thickness in the 
total study population. The valves in the ipsilateral leg of the patients are often 
damaged by the thrombosis and not likely to provide a reliable assessment. 
Therefore, as an assessment of the ipsilateral leg, the contralateral leg was used 
for all analyses in patients. To assess whether the valve thickness in the 
contralateral leg was representative for the valve thickness in the ipsilateral leg, we 
compared the valve thickness in the ipsi- and contralateral leg in patients where 




increased valve thickness increases the risk of VT, valve thickness was stratified at 
the 90th percentile as measured in control subjects. To study a dose-response 
relation, valve thickness was further stratified into quartiles. The risk of VT was 
assessed by calculating odds ratios (OR) with corresponding 95% confidence 
intervals (95% CI) after adjustment for age (continuous) and sex (dichotomous).  
We analysed the association between VCT and VT. As the cut-off value for reflux in 
deep veins is defined as a VCT>1 s,[15] we stratified the VCT at 1 s and calculated 
the risk of VT associated with prolonged VCT. To study the relation between VCT 
and valve thickness, linear regression was used.  
In patients where we were able to visualise the venous valve in the ipsilateral leg, 
we mapped the distribution of thrombi in the ipsilateral legs. Descriptive statistics 
have been used to explore the anatomical distribution of venous thrombi. 
Two reproducibility studies were conducted to test our measurement techniques. 
In the first study, from 14 participants valve thickness of the same image from the 
saved ultrasound examination was measured again by the same researcher without 
knowledge of the outcome of the first measurement. As such, we measured the 
reproducibility of the program VesselMass. In the second study, 11 participants 
underwent a second ultrasound examination to test the reproducibility of the 
operator. Two Bland-Altman plots were made to visualize the results. In the first 
Bland-Altman plot the difference in valve thickness between measuring the same 
image twice with VesselMass (depicted on the y axis) and the mean valve thickness 
of the 2 measurements (depicted on the x axis) was shown. In the second Bland-
Altman plot the difference in valve thickness between the first and second 
ultrasound examination (depicted on the y axis) and the mean valve thickness of 
the two measurements (also depicted on the x axis) was shown. Using the 
reproducibility method described by Bland and Altman, the 95% limits of 
agreement was calculated for repeated measurements. 95% of differences 
between the first and second measurement are expected to be less than 1.96 SD 




All analyses were performed using IBM SPSS Statistics 20.0 for Windows (SPSS 













289 identified controls 
215 eligible controls 
97 (45%) participated controls 
74 (26%) Excluded 
52 died 
15 cognitive decline 
2 cancer 
5 VT events 
118 (55%) No participation 
26 other GP 
42 no interest 
11 unreachable 






56 (35%) Excluded 
19 died 
17 cognitive decline 
1 cancer 
19 recurrence 
32 eligible cases from 
newly identified cases 
104 eligible cases from 
AT-AGE STUDY 
160 identified cases  
AT-AGE study 
61 newly identified cases 
August 2011 - July 2013 
136 eligible cases in 
BATAVIA study 
66 (49%) No participation 
3 other GP 
16 no interest 
11 unreachable 
36 no reason  
29 (48%) Excluded 
10 died 
7 cognitive decline 
1 cancer 
11 recurrence 




Figure 2 Schematic drawing of the valve measurement. Adapted from van Langevelde et al 
[7]. To standardize the measurements, the distance between the 2 circles, which 









General characteristics of the cases and control subjects are shown in Table 1. 
There were 31 (44%) women cases and 50 (52%) women control subjects. Mean 
age of cases and control subjects was 76 years. Among the 70 cases who 
participated, 69 (99%) underwent ultrasound examination and 69 (99%) 
completed the questionnaire; whereas all of the 96 participating controls (100%) 
completed both the ultrasound examination and questionnaire. Ultrasound 
examination took place after a mean duration of 31.9 months after VT diagnosis 
(range: 4-54 months). In 68 (97%) cases the side of the DVT was known. In the 
cases, in 45 (68%) individuals a valve was observed in the contralateral leg, and in 
34 (51%) in the ipsilateral leg. In the control subjects in 75 (78%) individuals a 




Table 1 Study characteristics 
 Controls 
N = 96 
Cases 
N = 70 
Female, n (%) 50 (52) 31 (44) 
Age, mean (95% CI) 76.0 (75.1-77.0) 76.1 (75.2-77.1) 
BMI, mean (kg m−2)† (range) 26.4 (18.3-38.5) 26.7 (19.6-38.1) 
Lower extremity surgery   
      Ever, n (%) 34 (35.4) 30 (42.9) 
      3 months prior to VT, n (%) 1 (1.0) 9 (12.9) 
Fracture, n (%)* 0 (0) 4 (5.7) 
Varicose veins, n (%) 28 (29.2) 24 (34.3) 
Valve thickness, mean (mm) (95% CI)   
     Right leg 0.36 (0.35-0.38)   
     Left leg 0.36 (0.34-0.37)  
     Contralateral leg  0.39 (0.36-0.42)  
VCT, mean (s) (range)   
     Right leg 0.4 (0.1-5.3)   
     Left leg 0.4 (0.2-3.8)   
     Contralateral leg  0.6 (0.1-5.6)  
 
*Three months prior to VT 






Table 2 Valve thickness in healthy control subjects 
 
* In 9 subjects no valve was present in either leg  
 
 
Risk of VT associated with increased valve thickness 
 
Table 2 describes the mean valve thickness in different subgroups of control 
subjects. In 50 control subjects a valve was observed in both legs and there was 
no difference in valve thickness  between the left (0.36 mm, 95% CI 0.34-0.37) 
and right (0.36 mm, 95% CI 0.35-0.38) leg in these control subjects. We found no 
difference in valve thickness between men and women, neither between a low 
(≤27) and high BMI (>27). Individuals below age of 80 had a mean valve 
thickness of 0.35 mm (95% CI 0.34-0.37), whereas those aged ≥80 years had a 
mean valve thickness of 0.38 mm (0.33-0.43), resulting in a mean difference of 
0.029 mm (95% CI -0.004-0.061). Mean valve thickness in the contralateral leg of 
the cases was 0.39 mm (95% CI 0.36-0.42), leading to a mean difference of valve 
thickness between cases and control subjects of 0.028 mm (95% CI 0.001-0.055). 
This is a 8% difference between cases and control subjects. Valve thickness above 
the 90th percentile as measured in control subjects (>0.44 mm), was associated 
Control subjects N = 96 Mean valve thickness (95% CI) 
Valve present, n (%) 87* (91) 0.36 (0.35-0.37) 
Subgroup   
     Men 44 0.37 (0.35-0.39) 
     Women 43 0.35 (0.33-0.37) 
Age   
     70-75 44 0.35 (0.34-0.37) 
     75-80 23 0.35 (0.33-0.38) 
     ≥80 20 0.38 (0.33-0.43) 
BMI   
     ≤27 53 0.37 (0.35-0.39) 
     >27 33 0.35 (0.33-0.37) 
Factor V Leiden  4 0.41 (0.15-0.67) 




with a 2.9-fold increased risk of VT (95% CI 1.0-8.0) compared with valve 
thickness ≤ 90th percentile. To study whether there was a dose-response relation 
between valve thickness and the risk of VT, we stratified valve thickness into 
quartiles. Using the first (lowest) quartile as the reference category, the OR 
remained similar for valve thicknesses in the second and third quartile with an OR 
of 0.9 (95% CI 0.3-2.7) and 0.7 (95% CI 0.2-2.3), respectively. The highest risk 
estimate was found in the fourth quartile (≥0.39): OR 2.3 (95% CI 0.8-6.5, Table 
3).  
 
Table 3 Odds ratios of VT with valve thickness stratified into quartiles  
Percentile Valve thickness at cut-
off, mm 
Controls, n Cases, n OR* (95% CI) 
< 25 < 0.32 19 8 1 (ref) 
25-50 0.32 – 0.35 24 9 0.9 (0.3-2.7) 
50-75 0.35 – 0.39 23 7 0.7 (0.2-2.3) 
≥ 75 ≥ 0.39 21 21 2.3 (0.8-6.5) 
 






Risk of VT associated with prolonged valvular reflux 
Mean VCT in the right leg of control subjects was 0.39 s (95% CI 0.26-0.51), in the 
left leg was 0.37 s (95% CI 0.26-0.48), generating a mean VCT in control subjects 
of 0.38 s (95% CI 0.30-0.46). Mean VCT in the contralateral leg of the cases was 
0.58 s (95% CI 0.32-0.84). We stratified the VCT at 1 s, and 4 control subjects and 
7 cases had a VCT ≥1 s, indicating that an VCT >1 s was associated with a 2.8 fold 
increased risk of VT compared with a VCT ≤1 s (OR: 2.8; 95% CI 0.8-10.4).Valve 
thickness was associated with VCT, i.e. for every 0.1 mm increase of valve 
thickness, VCT increased by 0.207 s (regression coefficient: 0.207).  
Characteristics of ipsilateral legs in cases 
In 19 patients a valve was observed in both legs and no difference was found 
between the contra- and ipsilateral leg in these individuals (mean difference of 
0.015, 95% CI -0.027-0.058). Of the 68 cases in whom the side of DVT is known, 
in 32 (47%) individuals no valve was observed in the popliteal fossa of the affected 
leg. Involvement of veins was studied in these 32 cases (Table 4), showing vena 
poplitea involvement in 13 cases, vena femoralis involvement in 11 cases, vena 
iliaca involvement in 3 cases and calf veins involvement in 7 cases. Overlap existed 
between vein involvements: 1 individual had involvement of both calf veins and 
vena poplitea, 3 individuals had involvement of calf veins, vena poplitea and vena 
femoralis, 1 individual had involvement of calf veins, vena poplitea, vena femoralis, 
and vena iliaca, 3 individuals had involvement of both vena poplitea and vena 
femoralis, and 2 individuals had involvement of vena poplitea, vena femoralis, and 
vena iliaca. Of 32 ipsilateral legs in which no valve was observed, the vena poplitea 
was the most often affected vein (n=13, 41%).  In 11 (46%) individuals with an 
affected popliteal vein (n=24), a valve was observed. Furthermore, in those whose 





Table 4 Characteristics of ipsilateral legs in cases 
 Ipsilateral legs 
N = 68 
Valves absent, n (%) 32 (47) 
Vein involvement known, n (%) 41 (60) 
Thrombus involvement of ipsilateral legs in absent of 
valves, n*: 




    Vena poplitea 13 
    Vena femoralis 11 
    Vena iliaca 3 
    Calf vein  7 
Vein combinations involved, n  
    Popliteal + femoral + iliac + calf veins 1 
    Popliteal + femoral + calf veins 3 
    Popliteal + femoral + iliac  2 
    Popliteal + femoral 3 





Reproducibility studies  
To assess the reproducibility of the software VesselMass, we included 14 images of 
14 participants and measured the valve thickness twice. The mean of the 
difference between the 2 measurements was 0.0143 mm (SD 0.06223). The 95% 
limits of agreement were -0.1077 to 0.1363, visualized by a Bland-Altman plot 
(Figure 3A). All of our measurements were within the 95% limits of agreement, 
except for one outlier.  
To assess the reproducibility of the operator, 11 participants underwent an 
ultrasound examination a second time. The mean of the difference between the 2 
measurements was 0.0045 mm (SD 0.07216) with 95% limits of agreement of -
0.1369 to 0.1459, also visualized by a Bland-Altman plot (Figure 3B). 
 
Figure 3A Bland-Altman plot of reproducibility of the software VesselMass. Valve thickness 
measurements were repeated for 14 images. The middle dashed line represents the mean 







Figure 3B Bland-Altman plot of reproducibility of the operator. Valve thickness 
measurements were repeated for 11 participants. The middle dashed line represents the 
mean difference in valve thickness. The upper and lower dashed lines represent the 95% 






In this population-based case-control study among individuals aged 70 years and 
older, valve thickness of the popliteal vein above the 90th percentile, as measured 
in the control group, was associated with a 2.9-fold increased risk of VT. No clear 
dose-response effect was observed in relation to increased valve thickness, but 
those in the highest quartile of valve thickness had 2.3-fold increased risk of VT 
(OR 2.3, 95% CI 0.8-6.5) compared with those in the lowest quartile. Valvular 
reflux, as measured by the valve closure time, was associated with a 2.8-fold 
increased risk of VT. Furthermore, a relation between valve closure time and valve 
thickness was found. For every 0.1 mm increase of valve thickness, VCT increased 
by 0.2 s. 
This is the first study to assess the risk of VT in relation to valve thickness and 
valve closure time in vivo in an elderly population. Previous studies were either 
human autopsy studies,[5, 6] or canine studies,[1] or not related to venous 
thrombotic disease[7].  
Thickening of the valve leaflets has been assigned to increase of collagen fibre 
bundles in cadaver studies including individuals ranging in age from 1 day to 84 
years.[5] Several studies have shown that a decreased compliance of vessel walls 
is also related to ageing.[17, 18] Together, they can disturb the normal blood flow 
and enhance stasis in the valve sinus, contributing to the development of 
thrombosis. Supporting this hypothesis is a previous study in which by using 
venography it was demonstrated that with increasing age valvular stasis 
progresses.[19] Also, a relation was found between frequency of VT and the 
number of valves in individuals.[20] The valvular sinus endothelium adapts to the 
hypercoagulable state by higher expression of protein C receptor (EPCR) and 
thrombomodulin (TM) and lower expression of von Willebrand factor (vWF), 
creating a thromboresistant phenotype compared to the luminal endothelium, as 




In almost half of all ipsilateral legs, no valve was detected during the ultrasound 
examination (47%). We’ve mapped the vein involvements in the legs with absent 
veins, and noted that in most cases (41%), the vena poplitea was involved. This 
might be related to the mechanical destruction of potential present valves due to 
the prior thrombus. A valve was more often observed when the popliteal vein was 
not affected (55%) than when the popliteal vein was affected (46%), however due 
to the limited power in these subgroups definite conclusions should be cautiously 
made.  
Our results regarding the reproducibility of the measurement software and 
operator showed that the reproducibility was good, as the mean difference 
between the measurements were small (0.0143 mm and 0.0045 mm) and the 
narrow limits of agreement are, in our opinion, an acceptable error level.  
In our study, the thickest valves were found in those aged ≥80 years, in line with 
previous research.[7] Other than age, no other determinants were identified for 
valve thickness. It is currently unclear whether the process of ageing of the venous 
valves is confined to the location of the thrombosis or whether it is a generic 
process and therefore it is measurable in veins elsewhere in the body, e.g., in the 
jugular veins. The fact that there was no difference in valve thickness between the 
ipsi- and contralateral legs of patients supports the hypothesis that thickening of 
valves is a generic process.  
The strengths of our study are the in vivo nature, the non-invasiveness of 
ultrasound, the specific attention to the elderly, and the ultrasonography 
information on both the contra- and ipsilateral leg. To our knowledge, presence of 
valves in contra- and ipsilateral legs have not been studied before. 
Some aspects of our study warrant comment. First, quality of ultrasonography 
examinations is directly related to operator skill, training, and experience.[23] To 
minimize inter-individual bias all examinations were performed by one operator 




39% of right legs of the control subjects we observed a valve in the popliteal fossa. 
Although this is not likely to substantially affect our data, the applicability and 
utility of this technique will be limited in clinical situations. In future studies, it may 
be beneficial to include the measurement of venous valves in multiple veins, e.g., 
including the vena femoralis to increase the number of potentially measurable 
valves. Third, due to the small number of participants, particularly when analysed 
in subgroups of valve thickness, the confidence intervals are wide indicating that 
larger studies to confirm our findings are warranted. Finally, valves in the 
contralateral legs in patients may not be a good representation for the valves in 
the ipsilateral legs. However, this is unlikely since no difference was observed 
between the valve thickness measured in the right and left leg of control subjects. 
Furthermore, in cases where valve thickness in both the ipsi- and contralateral leg 
could be measured, again, no difference was observed indicating that measuring 
the contralateral leg provides a good estimation of the valve thickness in the 
ipsilateral leg but increases the power of the study.  
To conclude, our study demonstrates an increased risk of VT associated with 
increased valve thickness, and increased valvular reflux of >1 s. Furthermore, 
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The role of the fibrinolytic system in the development of venous thrombosis (VT) is 
unclear. We studied the risk of first and recurrent VT associated with reduced 
fibrinolysis, as measured by clot lysis time (CLT). We also studied the relationship 
between CLT and thrombin generation to determine if any relationship between 
CLT and VT was affected by thrombin generation. Analyses were performed in the 
THE-VTE Study, a two-centre population-based case-control study, including 579 
patients and 338 controls, with patients followed from the event to determine 
incidence of recurrent VT. Hypofibrinolysis was associated with a 1.8-fold increased 
risk of a first VT (95%CI 1.2-2.7). Adjustment for sex, age, study location and 
Endogenous Thrombin Potential (ETP) did not change the result. The risk of VT 
was 2.9-fold increased when the 90th percentiles of prolonged CLT and high ETP 
were combined, with the highest risk for unprovoked first events (OR=4.2, 95%CI 
1.3-13.5). In the follow-up study the HR for a recurrent VT associated with 
hypofibrinolysis was 1.5 (95%CI 0.9-2.6). A weak dose response effect was 
observed in relation to prolongation of CLT and recurrent VT. Although 
hypofibrinolysis constitutes a risk factor for a first VT, an association with 





The incidence of venous thrombosis (VT) is 1 to 3 per 1000 person-years with a 
one-year cumulative incidence of recurrent VT of 7.4% after unprovoked VT and 
4.2% after a non-surgical trigger.(Baglin et al, 2003; Iorio et al, 2010) Risk of 
recurrence is very effectively decreased by anticoagulant treatment but this benefit 
must be balanced against the risk of anticoagulant therapy-associated major 
bleeding, which occurs in 2 to 3% of patients on treatment per year.(Bates et al, 
2012) Estimating the personalised predicted risk on an individual basis would allow 
appropriate targeting of long-term anticoagulant therapy.  
Since it has been difficult to establish the risk of recurrent venous thrombosis using 
clinical factors, attempts have been made to identify global laboratory markers 
which are associated with an increased risk of a recurrent VT.(Baglin, 2011) Most 
of these studies focussed on assays that provided a global assay for pro- and 
anticoagulant pathways.(Tosetto et al, 2012) Few studies have focussed on the 
association between fibrinolytic capacity and the risk of recurrent VT.(Meltzer et al, 
2010a;Traby et al, 2012) The clot lysis time (CLT) is influenced by levels of several 
proteins involved in fibrinolysis, i.e., plasminogen activator inhibitor-1 (PAI-1), 
alpha2-antiplasmin and thrombin activatable fibrinolysis inhibitor (TAFI). 
Determinants of CLT have been described previously (Meltzer et al, 2010b;Lisman 
et al, 2005) and this assay can be considered as a measure of plasma fibrinolytic 
potential.(Meltzer et al, 2007) CLT is a potential candidate for predicting the risk of 
a recurrent VT. 
Together with thrombomodulin thrombin forms a complex which activates 
TAFI.(Wang et al, 1998) Activated TAFI inhibits fibrinolysis by preventing 
plasminogen activation. Earlier studies have shown that increasing thrombin 
concentrations protect clots against lysis.(von dem Borne et al, 1995) This leads to 
the hypothesis that patients with a high thrombin generating capacity may also 




venous thrombosis not only directly but also indirectly by influencing fibrinolytic 
activity.  
The aim of this study was three-fold. First, to examine the association between 
CLT and the risk of a first and recurrent VT. Second, to examine the relationship 
between CLT and thrombin generation and third, to assess the composite 
association of CLT and thrombin potential with venous thrombosis. 
Materials and methods  
Study design and participants case-control study 
The Thrombophilia Hypercoagulability Environmental risk for Venous 
Thromboembolism study (THE-VTE) is a two center population-based case-control 
study. The design of THE-VTE has been described previously.(van, V et al, 2015) 
In short, from 2004 to 2008 consecutive patients aged 18 to 75 years with a first 
deep vein thrombosis (DVT) or pulmonary embolism (PE) were recruited from the 
anticoagulant clinic in Leiden, the Netherlands and the Addenbrooke’s Hospital in 
Cambridge, the United Kingdom, covering a well-defined geographical area in 
which all VT patients are admitted to, both outpatients and hospitalized patients. 
Partners of patients were invited as control subjects. Subjects with an active 
malignant disease were excluded from the study. Presence of a thrombus in the 
deep veins of the legs demonstrated with compression ultrasonography or Doppler 
ultrasound was considered as definite deep venous thrombosis (DVT). Pulmonary 
embolism (PE) was considered definite in case of a positive spiral computed 
tomographic or ventilation-perfusion lung scan findings.  
All participants gave written informed consent. The study was approved by the 
Medical Ethics committee of the Leiden University Medical Center, Leiden, the 






Within a few weeks after their VT, patients were invited to participate in the study 
by mailed letter and subsequent telephone contact (Leiden) or directly at their visit 
to the thrombosis clinic (Cambridge).The index date in the patients was defined as 
the date of diagnosis of the thrombotic event, in the control subjects this was 
defined as the date venous thrombosis of their partner. All participants were asked 
to complete a standardized questionnaire on acquired risk factors for venous 
thrombosis, such as surgery, pregnancy, oral contraceptive use, plaster cast, 
injury, malignancy, and immobilisation. All items in the questionnaire referred to 
the period prior to the index date. Three months after discontinuation of the 
anticoagulant therapy, a blood sample was taken from patients and controls in the 
anticoagulation clinic.  
In total, 796 patients and 531 control subjects were included. Of these, 626 
patients and 361 control subjects had donated blood without using oral 
anticoagulants. 93% of the patients (N=579) and 94% of the control subjects 
(N=338) had a valid CLT measurement and these participants were included in the 
current analyses. Idiopathic venous thrombosis was defined as venous thrombosis 
in patients without malignant disease in the five years prior to the index date and 
without surgery, injury, plaster cast, or confinement to bed for more than 4 
consecutive days in the three months prior to the thrombosis or oral contraceptive 
use or hormone replacement therapy at the time of the event. Body mass index 
(BMI) was calculated by dividing body weight (kg) by squared height (m2). 
Study design and participants follow-up study 
The patients included in THE-VTE case-control study were subsequently followed 
for the risk of recurrent venous thrombosis. A detailed description was published 
previously.(van, V et al, 2015) In Leiden, information on recurrent events was 
obtained from the patients via a short questionnaire and via the anticoagulation 




clinician who diagnosed the recurrence. In Cambridge, all potential recurrent 
events were seen and objectively diagnosed by one of the authors (TPB). This was 
done without prior knowledge regarding risk factors as measured in this study.  
The end of follow-up was defined as the date of the recurrence. In Leiden, in the 
absence of a recurrence, the end date of follow-up was the date of filling in the 
short questionnaire (which was sent annually to all participating patients). If a 
patient did not fill in a questionnaire they were censored at the last date known to 
be recurrence free, i.e., the last visit to the anticoagulant clinic, date of death or 
emigration, or the last time the patient was known to be recurrence-free from 
information of the THE-VTE case-control study. In Cambridge, recurrence status 
was checked on the first of July 2013. In the absence of recurrence or death, this 
date was registered as the end of follow-up. The start of follow-up was the date of 
termination of anticoagulation after the first event. In total 52 (8.3%) patients did 
not complete follow-up either due to death (n=21) without recurrence or not 
replying to further queries after a last visit at the anticoagulation clinic (n=13) or 
at a later point in time during follow-up (n=18).  
Blood collection and laboratory analysis 
Blood was collected into 0.106 M trisodium citrate. Plasma was prepared by 
centrifugation for 15 minutes at 4000 rpm at room temperature and stored at -
80ºC. All assays were performed without knowledge of whether the sample was 
from a patient or a control, and of whether a recurrent thrombosis had occurred. 
All assays were performed in one lab (Cambridge).  
Clot lysis time assay 
Lysis of a tissue factor-induced clot by exogenous tissue-type plasminogen 
activator (t-PA) was studied by monitoring changes in turbidity during clot 
formation and subsequent lysis as described previously.(Lisman et al, 2005) In 




50-μL mixture containing phospolipid vesicles, t-PA (final concentration 56 ng/mL), 
tissue factor, and CaCl2 diluted in HEPES buffer (N-2-hydroxyethylpiperazine-N’-2-
ethanesulfonic acid) was added by the use of a multichannel pipette. In a kinetic 
microplate the optical density was 405 nm and was monitored every 20 seconds, 
resulting in a clot-lysis turbidity profile. The CLT was derived from this clot-lysis 
profile and defined as the time from the midpoint of the clear to maximum turbid 
transition, representing clot formation, to the midpoint of the maximum turbid to 
clear transition, representing the lysis of the clot.  
Endogenous thrombin potential assay 
Thrombin generation was measured with the ThrombinoscopeTM Assay, 
(Thrombinoscope BV, Maastricht, the Netherlands). Tissue factor (TF) was mixed 
with phospholipids (PL) and added to polypropylene 96-well microtitre plates 
(Greiner Bio-one Ltd, Stonehouse, UK). Plasma was then added and thrombin 
generation was triggered and monitored by addition of premixed flurophore and 
calcium solution. For the calibrator wells the TF-PL mix was replaced with a 
thrombin solution (660nmol/l). Innovin tissue factor (TF) was at a final 
concentration of 5pmol/l (Dade Behring, Milton Keynes, UK).  Tissue factor 
concentrations were confirmed with a Xa-based chromogenic assay (Actichrome 
TF, American Diagnostica). Phospholipids (PL) were at a final concentration of 
4μmol/l (Avanti Polar Lipids (Alabama, USA) and consisted of 20mol% 
phosphatidylserine, 20mol% phosphatidylethanolamine and 60mol% 
phosphatidylcholine prepared by repeated extrusion (Avestin extruder, Mannheim, 
Germany). 80μl of platelet poor plasma were tested in triplicate in parallel with a 
calibrator. 20μl of Z-Gly-Gly-Arg-AMC reagent at a final concentration of 0.417 
mmol/l per well (Bachem AG, Bubendorf, Switzerland) suspended in Buffer with 0.1 
mol/l CaCl2, 20mmol/l HEPES, 60mg/ml Bovine Serum Albumin, pH 7.35 (all Sigma 
Inc, St.Louis,MO, USA) was added by the automatic dispenser. For the internal 
calibrator PL was mixed with 20μl of thrombin calibrator solution (alpha2-




Netherlands)). Fluorescence was measured by a Fluoroscan reader (Thermo 
Labsystems, Helsinki, Finland). Fluorescence filters used were an excitation filter at 
390 nmol/l and an emission filter at 460 nmol/l as supplied by Thrombinoscope BV. 
The Thrombinoscope™ software was used to convert the fluorescence signal into 
nmol/l Thrombin activity with correction for the inner filter effect and thrombin 
bound to alpha-2 macroglobulin activity, as described by Hemker et al.(Hemker et 
al, 2003) Samples used for this study were not previously thawed. 
Statistical analysis  
We studied the association between venous thrombosis and a prolonged CLT in the 
total study population, and for provoked and unprovoked venous thrombosis 
separately. To analyse whether hypofibrinolysis increases the risk of VT, CLT was 
cut off at the 90th percentile as measured in control subjects. The risk of a first 
venous thrombosis was assessed by calculating odds ratio’s (OR) with 
corresponding 95% confidence intervals (95% CI) according to Woolf’s method 
after adjustment for age (continuous), sex (dichotomous), and study location 
(dichotomous). We additionally adjusted for ETP to assess the extent to which the 
association between prolonged CLT and venous thrombosis is modified by ETP. To 
analyse a dose-response relation, CLT was further stratified into quartiles.  
We assessed the relation between endogenous thrombin potential and clot lysis 
time by performing a linear regression in control subjects. Lastly, we calculated the 
combined and separate effects of prolonged CLT and elevated ETP (both above the 
90th percentile) on the risk of VT.  
The cumulative incidence of recurrent venous thrombosis after 2 years was 
assessed and visualised by Kaplan–Meier survival analysis. The overall incidence 
rate of recurrent venous thrombosis with 95% confidence intervals (CI) was 
estimated. Hazard ratios for recurrent VT with 95% CI were estimated for the 
group with a prolonged CLT (i.e. above the 90th percentile as measured in the 




multivariable Cox regression analysis adjusted for age, sex, and study location. 
Again, we additionally adjusted for ETP to assess the extent to which the 
association between prolonged CLT and VT is modified by ETP. To study the dose-
response relation between CLT and recurrent VT, CLT was stratified into quartiles. 
We performed a sensitivity analysis in which we started the follow-up time from 
the moment of blood draw and additionally adjusted for the time between the VT 
event and blood draw. Two-year cumulative incidences of recurrent VT were 
estimated for quartiles of CLT. IBM SPSS Statistics 20.0 for Windows (SPSS Inc, 
Chicago, Ill) was used for data analysis. 
Results  
Characteristics of the 579 patients and 338 controls are shown in Table 1. The 
mean age at time of blood sampling for patients was 53 (95% CI: 52-55) and 
mean age of the control subjects was 54 (95% CI 53-56). Of the patients, 306 
(53%) were men compared with 128 (38%) of the control subjects. 357 (62%) 
Patients were diagnosed with DVT only, and 223 (38%) were diagnosed with PE 
with or without a DVT. The mean duration of anticoagulant therapy of the patients, 
i.e. vitamin K antagonists, was 5.7 months (95% CI 5.5-5.9). 
Mean CLT in the control subjects was 91.6 min (95% CI: 89-94). There was no 
difference in CLT between men (91.3 min. 95% CI: 88-95) and women (91.8 min. 
95% CI: 89-95) and the CLT increased by age (increase in CLT per year in 

















Case-control study                       
 Men (%) 306 (53) 128 (38) 
 Age mean (95%CI) 53.4 (52.3-54.6) 54.2 (52.9-55.5) 
 BMI (kg/m2)   
                 <20 11 11 
                 20-25 177 147 
                 >25 360 159 
 Use of oral contraceptives in women (%)   
                 Yes 90 (33) 30 (14) 
                 No 183 (67) 179 (86) 
 Pregnancy or post-partum in women (%)   
                 Yes 14 (5) 1 (1) 
                 No 255 (95) 202 (99) 
 Smoking (%)   
                 Current 249 (44) 141 (43) 
                 Former 201 (35) 123 (37) 
                 Never 119 (21) 68 (20) 
 Site of thrombosis (%)   
                 DVT 357 (62) - 
                 PE +/- DVT 222 (38) - 
 First event   
                 Unprovoked 270 - 
                 Provoked 283 - 
 CLT minutes mean (95%CI) 100.0 (98-102) 91.6 (89-94) 
 
Follow-up study 
 Observation time, mean (SD), yr 4.8 (1.8)  




Prolonged CLT associated with a first VT 
Mean CLT in the patients was 100.0 min (95% CI: 98.0-102.1) and the mean CLT 
difference between patients and control subjects was 8.4 min (95% CI: 5.2-11.7) 
longer for patients. After adjustment for age, sex and study location, 
hypofibrinolysis, i.e., CLT above the 90th percentile as measured in control subjects 
(>122 minutes), was associated with a 1.8 fold increased risk of a first VT 
compared with a CLT ≤ 90th percentile (OR 1.8, 95% CI: 1.2-2.8). Additional 
adjustment for ETP did not change the results (OR 1.6, 95% CI: 1.0-2.5). Analyses 
by type of event showed a 1.5 fold increased risk of VT (95% CI: 0.9-2.6) in the 
presence of hypofibrinolysis for provoked VT. For unprovoked VT, hypofibrinolysis 
was associated with a 2.1 fold increased risk (95% CI: 1.3-3.5). There was a clear 
dose-response relation between CLT and the risk of venous thrombosis with the 
highest risk of thrombosis for those with a CLT in the highest quartile (>105 
minutes) compared with the lowest quartile (<76 minutes): OR 2.7, 95%CI: 1.8-
3.9 (Table 2). The thrombin potential was positively associated with the CLT in 
control subjects, i.e., for every 100 units increase in ETP levels, an increase of 1.12 







Table 2 Dose-response relation CLT and risk of first VT 
Quartiles 
CLT 




1 84 93 76.1 1 (ref) 
 
2 85 93 86.7 1.0 (0.7-1.6) 
3 85 153 104.5 1.7 (1.1-2.5) 
4 84 240  2.7 (1.8-3.9) 
 
CLT, clot lysis time; VT, venous thrombosis; OR, odds ratio; 95% CI, 95% confidence 
interval. 
*Adjusted for sex, age, study site. 
 
Relative to individuals with both a normal CLT and a normal ETP, we found that 
individuals with a prolonged CLT but a normal ETP had a 1.7 fold increased risk of 
venous thrombosis (OR 1.7, 95% CI 1.1-2.7, Table 3). The risk was also 1.7 fold 
increased for individuals with an elevated ETP only (OR 1.7, 95% CI: 1.0-2.7). The 
risk was highest for individuals with a prolonged CLT and an elevated ETP, i.e., a 
2.9-fold increased risk of  VT (OR 2.9, 95% CI: 1.1-8.0). The highest risk was 
found in individuals with unprovoked first VT (OR 4.2, 95% CI: 1.3-13.5). In 
patients with a provoked first event the risk was 2-fold increased (OR 2.1, 95% CI: 
0.7-6.8). 
Prolonged CLT associated with recurrent VT 
After a mean follow-up period of 4.8 years, 78 out of 579 patients had a recurrent 
thrombotic event (13.5%, Table 1). The overall incidence rate was 27.9 per 1000 
person years (95% CI: 21.7-34.1). The two-year cumulative incidence of recurrent 
VT was 7.4% (95% CI: 5.3-9.6). The two-year cumulative incidences of recurrent 
VT in quartiles of CLT are given in table 4 (Figure 1). After adjustment for age, sex 
and study location, the hazard ratio for recurrence in patients with hypofibrinolysis 




95% CI: 0.9-2.7). Subgroup analyses showed no difference in the risk of 
recurrence associated with hypofibrinolysis after a provoked VT or unprovoked VT 
(HR 2.0; 95% CI: 0.8-5.0 for provoked VT and HR 1.5; 95% CI: 0.7-3.2 for 
recurrence after an unprovoked VT). Relative to individuals with a CLT in the 
lowest quartile (as measured in the control subjects), the risk of a recurrence 
increased from 1.5-fold (95% CI: 0.6-3.7) in individuals with a CLT in the second 
quartile to a 1.9-fold (95% CI: 0.9-4.1) increased risk of a recurrent event for 
those with a CLT in the fourth quartile. Sensitivity analysis showed no differences 
in risk estimates when follow-up time was started from the moment of blood draw 
and when additional adjustment for the time between VT even and blood draw 































































































































































































































Figure 1 Cumulative incidence of recurrent thrombosis. Patients with CLT’s in quartiles, cut-
off as measured in control subjects of the case-control study. 
 
No. at risk 
P<25 92 87 76 15 
P25-50 92 81 65 20 
P50-75 152 136 120 41 


















1 8/85 0.5 (-0.1-1.1) 1 (ref) 
 
2 12/81 1.4 (0.4-2.3) 1.5 (0.6-3.7) 
 
3 18/135 1.9 (0.8-3.0) 1.3 (0.6-3.0) 
 
4 40/200 3.6 (2.1-5.1) 1.9 (0.9-4.1) 
*adjusted for sex, age, study site 
 
Discussion  
In this study we aimed to investigate the association between CLT and a first and 
recurrent VT. Hypofibrinolysis, defined as CLT above the 90th percentile as 
measured in the control group, was associated with a 1.8-fold (95% CI: 1.2-2.8) 
increased risk of a first VT. A clear dose-response relationship was found between 
CLT and the risk of first VT: individuals with a CLT in the highest quartile had a 
2.7-fold (95% CI: 1.8-3.9) increased risk of a first VT compared to individuals with 
a CLT in the lowest quartile. Additionally, the risk of first venous thrombosis was 
highest in individuals with both a prolonged CLT and a high ETP (both above 90th 
percentile), i.e., these individuals had a 2.9-fold (95% CI: 1.1-8.0) increased risk of 
a first thrombotic event compared to individuals with a normal CLT and ETP (i.e. 
under the 90th percentile). In the prospective cohort study formed from the cases 
in the case-control study there was a weak association of hypofibrinolysis with 
recurrent VT (HR 1.5, 95% CI: 0.9-2.6). A slight dose response effect was 




CI: 0.9-4.1) increased risk of a recurrent event in patients in the highest quartile 
for CLT compared to those in the lowest.  
The findings from our case-control study are in line with previous studies reporting 
an increased risk of a first venous thrombosis associated with hypofibrinolysis, as 
shown in Table 5.(Lisman et al, 2005;Meltzer et al, 2008) Meltzer et al as well as 
Lisman et al reported a 2-fold increased risk of venous thrombosis associated with 
a prolonged clot lysis time. They also found a dose-response relation between 
hypofibrinolysis and venous thrombosis. 
Because hypercoagulability and hypofibrinolysis are both risk factors for venous 
thrombosis and are related, we hypothesized that reduced fibrinolysis and 
increased thrombin generation may each increase the risk for a first venous 
thrombosis, and modify the effects. The CLT assay is a measure of overall 
fibrinolytic activity and the ETP assay a measure of the most important 
determinant of hypercoagulability: thrombin. We found, as expected, the highest 
risk of first venous thrombosis in patients with elevated ETP and prolonged CLT 
(>90th percentiles in controls for both assays). In addition, as might be anticipated, 
the association was strongest in patients with a first unprovoked event. These 
results again confirm previous reports of the risk of VT when both 
hypercoagulability and hypofibrinolysis are combined. Our novelty is that we 
measured ETP as an estimate of hypercoagulability, while other reports measured 
use of oral contraceptives in women.(Meltzer et al, 2008) Previous studies have 
shown that the thrombin/thrombomodulin complex activates TAFI and this inhibits 
fibrinolysis (Bouma & Meijers, 2003), thereby leading to prolonged clot lysis time. 
Based on these findings we studied the association between CLT and ETP. We 
demonstrated an association between hypofibrinolysis, as measured by CLT, and 
an increased thrombin generating potential. This supports the hypothesis that 
increased thrombin generation leads to reduced clot lysis, probably as a result of 


























































































































































































































































































































































This result is in contast to only one previous report, in which CLT was not 
influenced by the thrombin-generating capacity of the plasma.(Lisman et al, 2005)  
We found a weak association between CLT and recurrent VT. The magnitude of 
the association would not be strong enough to give measurement of CLT clinical 
utility in personalising decisions in individual patients regarding the duration of 
anticoagulant therapy. Conflicting  results have been found in previous studies. No 
relationship between fibrinolysis and recurrent VT was found by Crowther et al 
(Crowther et al, 2001) or in the Leiden Thrombophilia Study.(Meltzer et al, 2010a). 
Eichinger et al reported an association with recurrent VT in patients with the 
highest TAFI levels (Eichinger et al, 2004) and a moderate increase in recurrence 
risk in association with prolongation of the CLT in women but not men.(Traby et al, 
2012) Taken together with our study the results of previous studies do not indicate 
a clinical use for measurement of CLT in the prediction of VT recurrence risk. 
However, future studies are needed to determine the definite role of the fibrinolytic 
system in predicting recurrent VT. 
The strength of our study is that all data were collected in the same manner for all 
participants and all venous thrombotic events were objectively diagnosed. 
Furthermore, all patients were followed-up for a mean period of nearly 5 years. 
Another strength of our study is that the same operator performed all CLT analyses 
to eradicate the bias that may be caused by the use of different techniques.  
A potential weakness of our study, and case-control studies in general, is that 
blood was drawn after the thrombotic event. The associations found between 
laboratory parameters and the risk for venous thrombosis could be a consequence 
rather than cause of the disease. We investigated if this was the case this by 
analysing whether the CLT changed over time. After stratifying the time between 
the index date and the blood draw (≤6 months versus >6 months), we calculated 
the mean difference of CLT between ≤6 months and >6 months. The mean 
difference was 1.7 min (95% CI: -4.0-7.4), therefore, no relation was found 




Another limitation of our study is that levels of fibrinolytic proteins, such as 
plasminogen, plasmin-alpha2-antiplasmin complex, and PAI-1 have not been 
measured in THE-VTE population. As a result, potential determinants of the CLT 
could not be elucidated from this study. 
In summary, our findings indicate that hypofibrinolysis is associated with venous 
thrombosis but measurement of CLT does not have clinical utility for the prediction 
and hence prevention of recurrent VT. The amount of thrombin generated is a 
determinant of clot lysis and so the amount of thrombin within a venous 
thrombosis may determine likelihood of embolisation and  residual vein occlusion 
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Summary and General discussion 
The aim of this thesis was to provide more insight into environmental and genetic 
factors that influence the risk of a first venous thrombosis (VT) in the elderly, i.e. 
individuals aged ≥70 years. In addition, we aimed to investigate the utility of the 
global clot lysis time assay in assessing the risk of a first and recurrent VT, initially 
in a younger population (≤75 years). In this chapter we provide a summary of our 
main findings, put them in an etiologic context and give suggestions for future 
research. 
Main findings 
Conventional risk factors of VT in the elderly 
In chapter 2 we explored the association between three inflammatory airway 
diseases, bronchitis, COPD, and asthma, and the risk of a first VT in the AT-AGE 
study. Using a detailed questionnaire on risk factors for a first venous thrombosis, 
we obtained information on comorbidities, including COPD, asthma and bronchitis. 
We confirmed the presence of COPD, asthma and bronchitis by reviewing the 
participants’ medication use, which was validated by examining pill bottles during 
the home visits. Still, misdiagnoses are frequent, especially in the elderly. Asthma 
and COPD both overlap and converge in the elderly.1-3 Our results show that for a 
number of patients diagnoses indeed overlapped. For this reason, we considered 
all diagnoses together, but we also calculated the risk of VT associated with the 
three inflammatory airway diseases separately. Presence of any airway disease 
increased the risk of VT 1.7-fold (95% CI 1.2-2.4), the risk of DVT alone 1.2-fold 
(95% CI 0.7-1.9), and the risk of PE 2.2-fold (95% CI 1.5-3.3). We observed that 
the presence of either bronchitis, COPD or asthma was more clearly associated 
with an increased risk of PE, and not or only weakly, with the risk of DVT. A 
possible explanatory mechanism is that inflammatory airway diseases predispose 
to local prothrombotic state and therefore give rise to a local development of 




studies suggest inflammation has a role in the pathogenesis of VT.4-7 C-reactive 
protein (CRP) is an acute-phase protein whose levels rise following tissue injury or 
inflammation. CRP has therefore been associated with cardiovascular disease and 
measurements of CRP levels proved to be a valuable predictor of the risk of future 
cardiovascular events.8 Therefore, the hypothesis that CRP might also be involved 
in the onset of VT has emerged, as reviewed by Lippi.9  
Contrary to the effect of lung diseases on the risk of VT as specific for PE, 
as discussed above, several risk factors for VT have been shown to increase the 
risk of a DVT but not, or to a much lesser extent, the risk of a PE.10 The ‘factor V 
Leiden paradox’ is the observation that the factor V Leiden G1691A mutation is at 
most a mild risk factor for isolated PE, whereas the risk of DVT is substantially 
increased.11,12 We have shown that the ‘factor V Leiden paradox’ can also be 
observed in the elderly. Individuals with the factor V Leiden variant had a higher 
risk of DVT (OR 3.0, 95% CI 1.5-6.0) than of PE (OR 1.6, 95% CI 0.7-3.1), and 
this difference remained after exclusion of patients with airway diseases.  
In chapter 3, we studied the risk of a first VT after the age of 70 years in 
association with several hereditary risk factors: factor V Leiden and prothrombin 
G20210A mutations, a positive family history of VT and non-O blood group. The 
most common prothrombotic variants are the factor V Leiden and prothrombin 
G20210A mutations, with an overall incidence of carriers of 2-5% among 
Caucasians.13-16 We showed that the risk of VT was 2.2-fold increased in factor V 
Leiden carriers (95% CI 1.2-3.9), 1.4-fold increased in prothrombin G20210A 
mutation carriers (95% CI 0.5-3.9), and 1.3-fold increased in those with non-O 
blood group (95% CI 1.0-1.8). Positive family history of VT  was associated with a 
2.1-fold increased risk of VT (95% CI 1.5-3.1). A previous large cohort study on 
the association between the factor V Leiden and prothrombin G20210A mutations 
and the risk of VT, was consistent with our results: the mutations were associated 
with an increased risk of VT in the elderly.16,17 Studies performed in younger 
individuals show us that factor V Leiden and prothrombin G20210A mutations 
increase the risk of VT 3- to 8-fold.14,18 In our study, we found these risk estimates 
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to be lower, OR 2.2 and OR 1.4 respectively. In this thesis two probable 
suggestions are given for this observation. First, because the elderly have a higher 
absolute risk of VT, individual risk factors have smaller relative effects than in 
middle-aged individuals. Or, in other words, whereas the relative risks are smaller 
than in the young, absolute risk differences for carriers versus non-carriers are 
substantial, given the high baseline risk in the elderly. Second, attrition of 
susceptibles: susceptible individuals with the factor V Leiden or prothrombin 
G20210A mutations are likely to develop VT earlier in life, which may have led to 
lower relative risks at older age. 
In chapter 3 we also found that a positive family history of VT in first-
degree relatives increased the risk of VT in the elderly 2.1-fold (95% CI 1.5-3.1). 
Family history is a feasible and global genetic risk assessment method for several 
clinical conditions.19 Therefore not surprisingly, several other case-control studies 
have also examined the relationship between family history and VT risk in first-
degree relatives. Two American20,21 and five European studies22-26 have found 
similar risk estimates, ranging from 2.2 to 3.0. These consistent results indicate a 
possible role of family history of VT in clinical decision rules of VT, not only in 
those younger than 70 years, but also in the elderly. Another important issue is the 
positive predictive value of family history of VT for a genetic risk factor for VT, 
specifically for the factor V Leiden and prothrombin G20210A mutations. We found 
in our study that 97 cases had a positive family history of VT. Among them 11 had 
either of the two mutations, which resulted in a positive predictive value of family 
history for carrying a prothrombotic variant of 11%. The low predictive value of 
family history for thrombophilias was also reported in previous studies24,25,27,28 
suggesting the presence of other, known or unknown, genetic factors influencing 
the risk of VT. The predictive value is determined by both the sensitivity and 
specificity of the predictor (i.e. assessment of a positive family history) and the 
prevalence of the predicted quality in the population being tested (i.e. factor V 
Leiden and prothrombin G20210A mutations). The interpretation of a positive or 




prevalence of the disease in that particular setting. Therefore, interpretation of the 
clinical validity of family history as a diagnostic tool to detect the factor V Leiden or 
prothrombin G20210A mutations should be made with caution.  
ABO blood group is believed to contribute to VT risk through modifications 
of von Willebrand Factor (VWF) and factor VIII (FVIII) levels in plasma.29-31 
However, several studies have shown that ABO blood group remains associated 
with an increased risk of VT even after adjustment for VWF or FVIII levels.32,33 
These results suggest that ABO may contribute to VT risk by additional other 
mechanisms than just modifications of VWF and FVIII.31 For example, genome-
wide association studies have linked the ABO locus to different types of cancer, a 
situation apt to VT occurrence.34,35  
Veins and valves in the elderly 
In chapter 4 we assessed the association between clinical features of venous 
insufficiency, such as history of varicose veins, leg ulcer or leg oedema, and the 
risk of VT in the AT-AGE study. We found that individuals who report a history of 
varicose veins or leg ulcer or who had leg oedema in the 3 months prior to the 
index date, were at an increased risk of VT (OR 1.6, 95% CI 1.2-2.3 for varicose 
veins, OR 3.0, 95% CI 1.5-6.2 for leg ulcer, OR 2.9, 95% CI 1.9-4.3). A leg ulcer is 
the most severe expression of venous insufficiency.36 Leg oedema as a result of 
long-term venous insufficiency could lead to mediator release and inflammation in 
the veins.37,38 Varicose veins are caused by a loss of vessel wall balance: venous 
hypertension leads to vein dilation, distortion, leakage, and inflammation, causing 
valve and wall disease and reflux.39,40 The resulting valve dysfunction and reflux 
lead to a prothrombotic microenvironment, prone to VT.41 In a previous study it 
was shown that valve thickness increased with age.42 The authors hypothesized 
that the increased risk of VT in the elderly could partly be explained by thicker 
valves in the elderly. In chapter 6 we investigated the risk of VT in presence of 
valve dysfunction, as a result of ageing, and reflux. We set up the BATAVIA study 
and we found on the one hand an association between thickened venous valves 
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and the risk of VT, and on the other hand an association between an increased 
valvular reflux and the risk of VT. Valve thickness of the popliteal vein above the 
90th percentile, as measured in the control group, was associated with a 2.9-fold 
increased risk of VT. Valvular reflux, as measured by the valve closure time, was 
associated with a 2.8-fold increased risk of VT. Furthermore, a relation between 
valve closure time and valve thickness was found. For every 0.1 mm increase of 
valve thickness, valve closure time increased by 0.2 s. Recently, studies on mouse 
models have identified several mechanisms that regulate venous valve 
development and maintenance. Mice deficient in Connexin37 entirely lack venous 
valves.43 Continuous integrin-α9 and ephrin-B2 signaling was found to be required 
for the maintenance of valves, since removal of either function results in regression 
of valve leaflets.44 In another study conducted in individuals with and without a 
mutation in the FOXC2 gene, a strong association was observed between those 
with the mutation and the presence of primary venous valve failure.45 In this study, 
as in ours, flow in the opposite direction – reflux – is used as a surrogate for valve 
failure. Further insight in these mechanisms could improve our understanding of 
failure and destruction of venous valves.  
In chapter 5 we investigated the distribution of thrombi in the AT-AGE 
study. Ageing may alter the venous circulation, resulting in a specific thrombi 
distribution pattern in the elderly.46 We found in the AT-AGE study that PE (with or 
without DVT) occurs more often than DVT (58.6% versus 41.4%). This is in 
contrast to studies conducted in young and middle-aged individuals in which the 
incidence of DVT is always higher than the incidence of PE.47-49 Furthermore, DVT 
occurred more often on the left side, and the popliteal and femoral veins were the 
most prevalent sites of thrombi. Left-sided predominance of DVT may be explained 







In chapter 7 we found that hypofibrinolysis, defined as clot lysis time above the 
90th percentile as measured in controls, increases the risk of a first VT 1.8-fold 
(95% CI 1.2-2.8) in THE-VTE study. There was a clear dose-response relationship 
between clot lysis time and the risk of a first VT, strengthening the notion of a 
causal relationship.51 Additional adjusting for endogenous thrombin potential did 
not change the results. In the cohort study of patients followed after their first VT, 
we found a weak association between hypofibrinolysis and recurrent VT (HR 1.5, 
95% CI 0.9-2.6). Additional adjustment for endogenous thrombin potential did not 
affect the risk of recurrent VT. The two assays used in this study link the 
coagulation and the fibrinolytic systems. The clot lysis time assay is a measure of 
overall fibrinolytic activity whereas the endogenous thrombin potential assay is a 
measure of the most important determinant of hypercoagulability: thrombin 
generation. When large amounts of thrombin are present, thrombin activatable 
fibrinolysis inhibitor will be activated. We hypothesized that increased thrombin 
generation would lead to decreased fibrinolysis and therefore to longer clot lysis 
time.52 This hypothesis was supported by our observation of an association 
between hypofibrinolysis and an increased thrombin generating potential. Currently 
prediction models are being developed to identify individuals with an increased risk 
of recurrent VT. In chapter 7 we show that elevated clot lysis time is not 
associated with the risk of recurrent VT, which suggests that screening for 
hypofibrinolysis or including clot lysis time in prediction models of recurrent VT 
would be of no value in the prevention of a recurrent event.  




The prevalence of obstructive airway diseases have increased in Western countries 
over the past decades, leading to a major health burden worldwide.53 Future 
studies are needed to evaluate diagnostic strategies in elderly patients with airway 
diseases. In thrombosis research predictive biomarkers are needed that can 
identify low- and high-risk elderly individuals for VT. Evaluating markers such as 
CRP9 could be valuable in determining which (hospitalized) patients would receive 
benefit from VT prophylaxis or prolongation oral anticoagulant therapy after a first 
VT. Furthermore, it’s important to take the coexisting need for other medications 
into account, increasing the risks of side effects of oral anticoagulants in the 
elderly.  
In the AT-AGE study we excluded individuals with cancer, receiving cancer 
therapy, and those who received cancer therapy in the six months prior to the VT. 
Future studies are needed to investigate whether the association between ABO and 
VT is related to cancer, changes in the haemostatic system by ageing, and if so, by 
what mechanisms. In clinical practice information on family history of VT is easy to 
obtain, however it is not implemented in clinical decision rules of VT risk. Possibly, 
obtaining information on family history of VT in individuals aged 70 years or older 
could improve prediction of VT in the elderly. Future studies could examine 
different candidate genes of venous insufficiency.  
There is a lack of evidence associating genes with the development and 
severity of features of venous insufficiency. More studies are needed to confirm 
our results of the BATAVIA study, which to our knowledge is the first and only 
study examining the relation between VT risk and thickened venous valves and 
reflux in the elderly. Researchers should investigate whether valve thickness is 
related to post-thrombotic syndrome and whether valve thickness and function can 
predict post-thrombotic syndrome. Identifying patients at high risk of developing 
post-thrombotic syndrome would help improve the management of patients with 




patients with high or low risk of recurrent VT. Future studies should link clinical 
patient characteristics in the elderly, such as frailty, with laboratory testing to 
develop a scoring model that allow assessing the risk of recurrent VT.  
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Veneuze trombose is obstruerende stolselvorming in de veneuze bloedvaten, vaak 
veroorzaakt door een verstoring in de bloedstolling. Het bloedstolsel sluit het 
bloedvat geheel of gedeeltelijk af en dit geeft klachten van pijn, een rode kleur en 
zwelling van het been. Dit noemen we een trombosebeen. Als een deel van het 
bloedstolsel afbreekt en met de bloedstroom mee in de longen belandt, is er 
sprake van een longembolie. Een longembolie geeft kortademigheid en pijn op de 
borst en, afhankelijk van de grootte van de embolie, kan de bloedtoevoer naar de 
longen vanuit de rechter kamer van het hart geheel belemmerd raken, waardoor 
de patiënt in korte tijd kan overlijden. Leeftijd is een belangrijke risicofactor voor 
veneuze trombose. In de leeftijdscategorie 25-30 jaar komt veneuze trombose 
ongeveer bij 1 per 10 000 personen per jaar voor, terwijl bij 85+ers veneuze 
trombose bij 8 per 1000 per jaar voorkomt.  
In dit proefschrift worden risicofactoren van veneuze trombose bij ouderen 
onderzocht. We onderzoeken verschillende verworven en genetische afwijkingen 
die in ouderen het risico op trombose kunnen beïnvloeden . Daarnaast bestuderen 
we de rol van verouderde veneuze kleppen en symptomen van veneuze 
insufficiëntie op het risico op trombose. Tot slot bekijken we de rol van de globale 
assay ‘clot lysis time’ om te zien of we met deze assay een recidief trombose 
kunnen voorspellen. 
In dit proefschrift worden de resultaten van drie klinische onderzoeken 
gepresenteerd. 
Het AT-AGE onderzoek 
‘AT-AGE’ staat voor Age and Thrombosis, Acquired and Genetic risk factors in the 
Elderly. Het AT-AGE onderzoek is een patiënt-controle onderzoek uitgevoerd in 
Leiden en Burlington, Vermont om risicofactoren voor veneuze trombose in 




veneuze trombose kregen na hun 70e levensjaar en controles die nog nooit een 
veneuze trombose hadden gekregen, gevraagd mee te doen. Ouderen worden 
vaak uitgesloten van wetenschappelijk onderzoek, vanwege moeilijkheden om het 
studiecentrum te bereiken, visuele en cognitieve comorbiditeiten, of allerlei andere 
leeftijdgerelateerde beperkingen. Daarom hebben we in het AT-AGE onderzoek alle 
participanten thuis bezocht en door middel van interviews de vragenlijsten 
ingevuld. We hebben 401 patiënten met een eerste trombose en 431 controles 
zonder trombose geïncludeerd en bezocht.  
Het Batavia onderzoek 
Leeftijd is een belangrijke risicofactor voor veneuze trombose. Veroudering van de 
vaatwand in bloedvaten leidt tot een trombogene omgeving. In de veneuze vaten 
zijn kleppen aanwezig om te assisteren bij de richting van de bloedstroom. In de 
onderbenen voorkomen veneuze kleppen terugstroom van het bloed naar lagere 
regionen. In eerder Leids onderzoek  is naar voren gekomen dat veneuze kleppen 
dikker worden naarmate ze verouderen. Ook de functionaliteit van de kleppen 
wordt slechter. 
In het Batavia onderzoek bestuderen we de associatie tussen verouderde 
veneuze kleppen en het toegenomen risico op veneuze trombose. ‘Batavia’ staat 
voor Biology of Ageing and Thrombosis: Appraisal of Valve thickness and function, 
an In vivo Assessment. Ook het Batavia onderzoek is een patiënt-controle 
onderzoek. In dit onderzoek hebben we enerzijds de associatie tussen klepdikte en 
het risico op trombose en anderzijds de associatie tussen klepfunctie en het risico 
op trombose bestudeerd.  
De deelnemers van het AT-AGE onderzoek zijn gevraagd om mee te doen 
in het Batavia onderzoek. Alle participanten waren ≥70 jaar. De deelnemers 
werden uitgenodigd naar het LUMC voor een echo-onderzoek om de dikte en 





Het THE-VTE onderzoek 
‘THE-VTE’ staat voor Thrombophilia, Hypercoagulability and Environmental risks in 
Venous ThromboEmbolism. Het THE-VTE onderzoek is uitgevoerd in Leiden en 
Cambridge, Verenigd Koninkrijk, om globale teststrategieën te ontwikkelen 
teneinde patiënten met een verhoogde stollingsneiging te identificeren. Globale 
assays zouden het mogelijk kunnen maken om patiënten met een verhoogd risico 
op een eerste en recidief trombose te herkennen. In Nederland zijn de patiënten 
geïdentificeerd uit de Trombosedienst in Leiden en in de Verenigd Koninkrijk zijn 
de patiënten geïdentificeerd in het Addenbrooke’s ziekenhuis in Cambridge. De 
partners van patiënten zijn gevraagd om als controles mee te doen. Alle 
participanten waren 18-75 jaar. De globale assay om fibrinolyse te meten is 
onderzocht voor het risico op een eerste en recidief trombose.  
In hoofdstuk 2 laten we zien dat aandoeningen van de luchtwegen bij 
ouderen, namelijk bronchitis, COPD, en astma, vooral het risico op een 
longembolie vergroten (odds ratio [OR] 2.2, 95% betrouwbaarheidsinterval [BI] 
1.5-3.3) en in mindere mate het risico op een trombosebeen (OR 1.2, 95% BI 0.7-
1.9). We hebben een hypothese geformuleerd om dit verschil in risico’s te 
verklaren. Lokale ontstekingen bij luchtwegaandoeningen zouden een aanleiding 
kunnen vormen om lokale trombose te veroorzaken. Toekomstig onderzoek zal 
moeten uitwijzen of lokale trombi, als gevolg van ontstekingen, longembolieën 
kunnen veroorzaken.  
Hoofdstuk 3 bevat de resultaten van genetische risicofactoren in ouderen 
(factor V Leiden mutatie, protrombine mutatie, non-O bloedgroep) alsmede een 
positieve familiegeschiedenis van trombose, en het risico op het krijgen van een 
eerste veneuze trombose. We zien dat de factor V Leiden mutatie het risico op 
trombose 2.2-keer verhoogt, protrombine mutatie 1.4-keer, non-O bloedgroep 1.3-
keer, en een positieve familiegeschiedenis van trombose 2.1-keer. We concluderen 
dat ook in ouderen genetische risicofactoren een rol blijven spelen bij het ontstaan 




goedkoop, en we stellen voor dat toekomstig onderzoek zich richt op het 
includeren van familiegeschiedenis in predictiemodellen voor trombose.  
In hoofdstuk 4 bekijken we klinische uitingen van veneuze insufficiëntie, 
namelijk oedeem, spataderen en ulcus cruris in de AT-AGE studie. We hebben het 
risico op veneuze trombose berekend bij aanwezigheid van deze klinische beelden. 
Het risico op trombose wordt 2.9-keer (95% BI 1.9-4.3), 1.6-keer (95% BI 1.2-
2.3), en 3.0-keer (95% BI 1.5-6.2) verhoogd bij aanwezigheid van respectievelijk 
oedeem in de onderbenen, spataderen en ulcus cruris.  
Hoofdstuk 5 wordt de anatomische verdeling gerapporteerd van veneuze 
trombose in patiënten ≥70 jaar. We zien dat bij ouderen longembolieën vaker 
voorkomen dan trombosebenen (53.7% vs. 43.6%), terwijl onderzoek uitgevoerd 
in jongere mensen ons leert dat het omgekeerde het geval is bij hen. Ook zien we 
dat een trombose in het linkerbeen vaker voorkomt (53.7%) dan trombose in het 
rechterbeen (43.6%).  
Resultaten van het Batavia onderzoek worden besproken in hoofdstuk 6. 
In verschillende post-mortem onderzoeken komt naar voren dat trombose vaak 
ontstaat rondom veneuze kleppen. Veneuze kleppen worden dikker naarmate men 
ouder wordt. Tussen de klep en de vaatwand circuleert de bloedstroom op een 
zeer lage snelheid, waardoor stase en een lage zuurstofspanning ontstaat. Dit leidt 
tot nog meer klepschade, en mogelijk tot klepdysfunctie die zich uit in reflux. Wij 
hebben gevonden dat een dikke klep en veneuze reflux risicofactoren vormen voor 
veneuze trombose in ouderen. Een verdikte klep deed het risico op trombose 2.9-
keer verhogen (95% BI 1.0-8.0), veneuze reflux langer dan 1 s deed het risico 2.8-
keer verhogen (95% BI 0.8-10.4).  
In hoofdstuk 7 wordt de relatie van een maat van het fibrinolytisch systeem, de 
‘clot lysis time’ (CLT), en het risico op veneuze trombose besproken. Naast een 
ongeremde stollingsneiging, kan ook een gestoorde fibrinolyse, de capaciteit om 




onderzoek is uitgevoerd in patiënten en controles ≤75 jaar van het THE-VTE 
onderzoek en laat zien dat een lange CLT een risico vormt voor een eerste 
trombose. In de vervolgstudie van THE-VTE zijn patiënten met een eerste veneuze 
trombose gemiddeld 4.8 jaar gevolgd om te bepalen of zij een recidief kregen. Een 
verlengde CLT bleek geen voorspeller te zijn voor een recidief trombose. 
Toekomstig onderzoek zal moeten uitwijzen of deze resultaten ook gelden voor de 
oudste ouderen (>75 jaar). Vooralsnog is er gering onderzoek aanwezig dat 
recidief trombose bij de ouderen kan voorspellen.  
Tot slot 
In dit proefschrift hebben wij risicofactoren voor veneuze trombose bij ouderen 
onderzocht. Onze resultaten laten zien dat luchtwegaandoeningen bij ouderen 
vooral het risico op longembolieën vergroten. Bij de etiologie van veneuze 
trombose spelen bij ouderen ook genetische risicofactoren nog steeds een rol. 
Verder laten we zien dat tekenen van veneuze insufficiëntie het risico op trombose 
bij ouderen vergroot, dat longembolieën vaker dan trombosebenen voorkomen in 
deze populatie, en dat verouderde veneuze kleppen een risicofactor vormen voor 
veneuze trombose. Toekomstig onderzoek is nodig om onze resultaten te 
bevestigen en om hoog-risico groepen te identificeren binnen de ouderen die in 
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